Functional and mechanistic characterization of ubiquitin fusion degradation 1 in MYC-driven leukemogenesis by Huiting, Leah
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2018
Functional and mechanistic
characterization of ubiquitin fusion
degradation 1 in MYC-driven
leukemogenesis
https://hdl.handle.net/2144/32980
Boston University
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Dissertation 
 
 
 
 
 
 
FUNCTIONAL AND MECHANISTIC CHARACTERIZATION OF UBIQUITIN 
FUSION DEGRADATION 1 IN MYC-DRIVEN LEUKEMOGENESIS 
 
 
 
 
by 
 
 
 
 
LEAH NICOLE HUITING 
 
B.A., Mount Holyoke College, 2013 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Doctor of Philosophy 
 
2018  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2018 by 
 LEAH NICOLE HUITING 
 All rights reserved  
Approved by 
 
 
 
 
 
 
 
 
First Reader _________________________________________________________ 
 Hui Feng, M.D./Ph.D. 
 Assistant Professor of Pharmacology and Experimental Therapeutics 
 
 
 
 
Second Reader _________________________________________________________ 
 David Langenau, Ph.D. 
 Associate Professor of Pathology 
 Harvard Medical School 
 
 Director of the Molecular Pathology Unit 
 Massachusetts General Hospital  
		 iv 
DEDICATION 
 
 
 
 
To my family and friends for their unconditional love and support. 
 
  
		 v 
ACKNOWLEDGMENTS 
 First and foremost, I would like to thank my mentor, Dr. Hui Feng, for providing 
me the opportunity to work in her lab. She graciously opened her laboratory and gave me 
the opportunity to not only use my skills as a chemist but become a biologist as well. 
Beyond maturing as a scientist, Dr. Feng fostered my abilities to not only act as a scientist 
but to think as a scientist. She aided in my development of critical thinking skills and 
encouraged my independence on project management. I am forever grateful for her 
unwavering support of both my academic and professional goals. Thank you for celebrating 
in all my accomplishments and for providing a lifelong mentorship. 
 I would like to express my immense gratitude and appreciation for the experimental 
guidance and support from Dr. Nicole Anderson, Dr. Haiwei Lian, Dr. Fabrice Laroche, 
Dr. Yanwu Wang, Dr. Dun Li and Dr. Ning Shen. These incredible scholars helped me 
learn new experimental techniques, offered their help in any capacity through which they 
could, and offered advice regarding my research. Their insights on science helped me 
become a better scientist and their company as colleagues brightened my days. 
 My research could not have been accomplished without an extraordinary group of 
undergraduate students: Yasmina Samaha, Boey Li, Joo Won Choi, and Andrew Lam. 
Their hard work contributed to numerous findings in my research and pushed my projects 
forward. Not only was I able to teach and mentor them, they were able to teach and mentor 
me. For their willingness to provide their time and effort towards my project, I will be 
forever grateful. For their friendship, I am forever more grateful. Similarly, I would like to 
express my appreciation to my fellow classmates and colleagues in the Shamim and Ashraf 
		 vi 
Dahod Breast Cancer Research Center. I couldn’t have asked for more supportive, 
hardworking, innovative, and joyful colleague and friend to begin and end this journey 
with- Amanda Bolgioni, I will forever be grateful for everything and I can’t wait to 
continue our scientific journeys and see where they take us. 
 I would like to thank the members of my dissertation advisory committee: Dr. 
Anurag Singh, Dr. Herbert Cohen, Dr. Neil Ganem, and Dr. David Langenau. Their 
time, scientific insights, perspectives, and guidance have been fundamental in both driving 
my research forward and ensuring I approach my research questions with the upmost 
scientific rigors. Particularly, I want to voice my appreciation to Dr. Singh for the 
additional time and commitments he undertook as the chair of my committee. 
 I must also extend my appreciation to faculty in the Pharmacology Department that 
have encouraged my scientific development both academically and professionally. Dr. 
Carol Walsh, Dr. David Farb, and Dr. Shelley Russek have established an excellent 
training program whose support for its students is unmatched. Moreover, Nadiayh 
Shaheed, Sara Johnson, Christina Cherel, and Wanda Roberts have ensured the 
seamless coordination and forward movement of the department. 
 Most importantly, I would like to thank my family and friends. I am extremely 
lucky to have the best friends in the world. Their support, comic relief, and excitement over 
my successes made this journey fly by. To my sister, thank you for your love, 
encouragement, and always picking up the phone-I am so lucky that you are mine. To my 
mom, thank you for your love, constant support, and ability to listen to me talk endlessly 
on the phone. Your generosity and friendship are invaluable and cherished. To my dad, my 
		 vii 
hero. I hope that one day I am half the incredible person you are. You continually provide 
the greatest encouragement, support, advice, and love. There are not enough ways to say 
thank you for all that you have so graciously provided me with, so I’ll keep trying to find 
more in the meantime. Last, but certainly not least, to my boyfriend Baker Logan. You are 
my rock. Thank you for being my happiness, joy, and best friend. I am so proud to be your 
girlfriend and going on this journey of life with you is the best decision I have ever made.  
  
		 viii 
FUNCTIONAL AND MECHANISTIC CHARACTERIZATION OF UBIQUITIN 
FUSION DEGRADATION 1 IN MYC-DRIVEN LEUKEMOGENESIS 
LEAH NICOLE HUITING 
Boston University School of Medicine, 2018 
Major Professor: Hui Feng, M.D./Ph.D., Assistant Professor of Pharmacology and 
Experimental Therapeutics 
 
ABSTRACT 
  Tumor cells often hijack endoplasmic reticulum (ER) mediated signaling to 
facilitate tumor progression by adapting to the cellular stress evoked by oncogene 
overexpression and adverse microenvironment. Despite the prevalence of MYC-driven 
cancers, how the MYC oncoprotein regulates ER stress response pathways during 
tumorigenesis remains incompletely understood. Here we show that MYC drives 
continuous upregulation of ubiquitin fusion degradation 1 (UFD1) during T-cell acute 
lymphoblastic leukemia (T-ALL) development. As the E2 component of an ER-associated 
degradation (ERAD) complex, UFD1 facilitates the elimination of misfolded/unfolded 
proteins from the ER.  We found that genetic and pharmacological disruption of UFD1 
function exacerbates ER stress and activates the unfolded protein response 
(UPR). Specifically, UFD1 knockdown in human T-ALL cells impairs ERAD and 
promotes the proapoptotic UPR through the PERK-CHOP-BCL2 axis. This effect is 
demonstrated by an upregulation of PERK, phospho-PERK and its downstream effector 
CHOP, as well as a downregulation of BCL2 and BCLxL. Indeed, CHOP inactivation or 
BCL2 overexpression is sufficient to rescue tumor-cell apoptosis induced by UFD1 
knockdown. Allelic loss of ufd1 in zebrafish similarly induces tumor-cell apoptosis and 
		 ix 
impairs MYC-driven T-ALL progression without affecting general animal health. These 
studies establish the UFD1-mediated ER stress response as an important mediator of MYC-
driven tumor progression and suggest strategies for targeted therapy in T-ALL, and perhaps 
other MYC-driven cancers. Although UFD1-specific inhibitors have yet to be developed, 
inhibitors that target the p97 co-factor in UFD1-mediated ERAD are readily available. 
Importantly, we show that treatment with CB-5083, a selective and oral bioactive inhibitor 
of p97, can effectively kill human MYC-overexpressing T-ALL patient cells ex vivo and 
inhibits tumor progression in zebrafish models of MYC-driven T-ALL.  Thus, CB-5083 
treatment may represent an effective targeted therapy for T-ALL, especially 
relapsed/refractory ones with gain-of-function NOTCH1 mutations and thus MYC-
overexpression. 		
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PREFACE 
Portions of Chapters I-IV in this dissertation are derived from a manuscript, entitled 
“UFD1 contributes to MYC-mediated leukemia aggressiveness through suppression of the 
proapoptotic unfolded protein response”, of which I am the first author, accepted and soon 
to be published in Leukemia, Nature Publishing Group.(ISSN 1476-5551) 
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CHAPTER ONE: Introduction 
A. The Molecular Pathogenesis of T Cell Leukemia and Lymphoma 
1. Introduction 
 T cell acute lymphoblastic leukemia (T-ALL) is an aggressive, hematologic 
malignancy stemming from immature lymphoid progenitors. This malignancy is 
characterized by diffuse malignant hematopoietic cells expressing immature T cell markers 
that have infiltrated the bone marrow.1 Additional hallmarks of this disease include 
chromosomal abnormalities and genetic alterations that are involved in the differentiation 
and proliferation of lymphoid progenitors. T-ALL is derived from the malignant 
transformation of immature cells of the T cell lineage.2 These T-ALL cells differ from 
normal thymocytes in their overexpression of oncogenes that arise from chromosomal 
translocations, mutations, and the constitutively active expression of signaling pathways 
that control the initial stages of thymocyte development.3 The development and diagnosis 
of T-ALL is associated with unfavorable pathophysiology such as high white blood cell 
count, bulky adenopathy, and in some instances lesions in the central nervous system 
(CNS).4   
T-ALL is the second most common acute leukemia with a reported 6,500 new 
diagnoses and approximately 1,400 deaths per year in the United States. The incidences of 
T-ALL are bimodal, largely affecting those in childhood years, with peak prevalence 
between two and five years (10-15% of ALL cases) or those of approximately 50 years of 
age and older (20-25% of adult cases).5,6 T-ALL is twice as prevalent in males as in 
females.7 Steady progress in the development of effective therapeutics has fortunately led 
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to a cure rate of more than 80% in children. Despite high response rates to induction 
chemotherapy, only 30-40% of adults will achieve long-term remission,8 which is 
compounded by the complexity, expense, and toxic effects of contemporary, multi-agent 
treatment protocols.9,10 An increase in the understanding of T-ALL pathobiology can be 
attributed to the discovery of new prognostic biomarkers and improved animal models of 
leukemia, providing momentum for the development of targeted, low cytotoxic 
therapeutics for improved treatment and outcomes.  
 
2. An Overview of T Cell Development 
 The molecular regulation of self-renewal and differentiation in long-term 
repopulating hematopoietic stem cells (LT-HSCs) is still poorly understood. It is well 
accepted that stem cells progressively differentiate to generate short term repopulating 
HSCs and multi-potential progenitors.11 The initiation of lymphoid commitment also bears 
the burden of not being well understood; however, several hematopoietic stem cell 
fractions have been proposed to represent actual lymphocyte progenitors. Within these 
stem cell populations, cells that are destined to become T cells will exit the bone marrow. 
In a chemotactic manner, and moderated by adhesion molecules, these cells will migrate 
through blood to the thymus.12, 13 Throughout this process, the thymus requires either 
continuous or periodic input from progenitor cells to maintain proper T cell development 
and to produce mature T cells.  
The first thymic immigrants are early T cell lineage progenitors known as double 
negative cells that present with the CD3- CD4-/lowCD8-CD25- CD44hiKIT+ 
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immunophenotype. Cells that then commit to the T cell lineage downregulate KIT 
expression and are denoted as DN2: CD4-CD8-CD25+CD44+. Subsequently in 
development, CD44 expression is downregulated followed by CD25 expression. These 
immunophenotypes are denoted as CD4-CD8-CD25+CD44- and CD4-CD8-CD25-CD44-, 
respectively.14 These T cell progenitors maintain intimate contact with thymic epithelia 
stromal cells. This contact is essential as the stromal cells express NOTCH ligands and 
produce essential growth factors that are involved in lineage fate decisions. Preceding pre-
T cell receptor (TCR) expression, thymocytes lose their essential dependence on NOTCH1, 
sonic hedgehog, and cytokine signaling permitting the differentiation of thymocytes into 
double positive cells: CD4+CD8+. These thymocytes can then enter the process of positive 
and negative selection wherein αβ T cell receptors and T cells exit the thymus as mature, 
singly positive CD4+ or CD8+ T cells.14  
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Figure 1.1. Schematic illustrating the differential, ordered expression of cell surface markers during 
αβ T cell development.  
The earliest developing thymocytes are denoted as double negative (DN) cells as they lack the expression of 
the co-receptors CD4 and CD8. The double negative population can be further divided based on the 
expression of CD44 (an adhesion molecule) and CD25 (Interleukin-2 receptor α chain). T cells are further 
differentiated through the expression of CD4 and CD8 and are termed double positive (DP) cells. Cells that 
fail to undergo beta-selection are subjected to apoptosis. 
 
T-ALL is thought to originate from various important genetic lesions in these 
lymphoid progenitor cells that are committed to differentiate into the T cell pathways. 
Based on analysis of available genomic data, each T-ALL case contains an accumulation 
of genetic alterations in: the NOTCH1 signaling pathway, cell cycle factors, transcription 
factors, epigenetic factors, extracellular growth factors, cytokines, signaling factors, and 
genes that contribute to translation and RNA stability. These mutations coordinately 
contribute to the transformation of normal T cells. T cells are transformed into an 
aggressive malignancy with impaired differentiation, improved survival characteristics, 
robust proliferation, altered Cell Metabolism, cell cycle, and homing throughout thymocyte 
development.1 These genetic alterations ultimately impart the capabilities of unlimited self-
renewal and induce developmental arrest at precise progenitor stages.15,16 
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3. The Pathophysiology of T Cell Acute Lymphoblastic Leukemia 
Established in 1997 and updated in 2008, the World Health Organization 
recognized a composite classification of ALLs. This composite classification drew from 
both the morphology and cytogenetic profile of leukemic blasts.17,18 General characteristics 
of the lymphoblast population in T-ALL include homogeneous blasts that are mainly small 
in size and a central, primarily rounded nucleus that can be identified in pathology samples. 
In adolescence there is a very high nucleocytoplasmic ratio, while adults are observed to 
have particularly indented nuclei. There are biologically different and clinically relevant 
groups of T-ALL that are recognized by their recurrence of translocations, genetic lesions, 
and differential commitment of T cells during T cell development.15  
 
a. Recurrent Translocations in T-ALL  
An abnormal karyotype is found in approximately 50% of T-ALL cases.3 Frequent 
chromosomal translocations in T-ALL involve the combination of strong promoter and 
enhancer elements from T cell receptor genes. While some transcription factor genes may 
be normally expressed in non-malignant thymocytes and have essential roles in the 
regulation of T cell ontogeny, other transcription factors are not expressed in normal 
thymocytes but are rather ectopically expressed by transformed cells in T-ALL. These 
types of translocations may occur during thymocyte development due to illegitimate TCR 
recombination leading to aberrant gene expression. Abnormal cell cycle control, 
proliferation, and differentiation of T cells are characteristic functional phenotypes in these 
instances.3  
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Translocations that occur with the greatest frequency, at a rate of approximately 
35% in both adults and children, are those of the TCR with various oncogenes. These 
translocations do not manifest into clinically relevant tumor presentation, but do result in 
hematopoiesis deregulation and impairment in cell differentiation. These translocations are 
t(1;14), t(10;14), and t(5;14); and involve the LIM domain only (LMO1 and 
LMO2),transcription activator like (TAL1),and nuclear receptor TLX  (TLX1 and TLX3) 
genes. Translocations that also bear no clinical burden but rather result in the constitutive 
activation of Abelson murine leukemia viral oncogene homolog (ABL) are: t(9;9)(q34;q34) 
and t(9;14)(q34;q32) involving the NUP214-ABL (nucleoporin 214) and EML1-ABL 
(echinoderm microtubule associated protein 1) genes respectively. The translocation 
t(8;14)(q24;q11) results in a lymphoma-like presentation preceding aggressive disease 
progression and poor clinical outcomes. Similarly, the 11q23 rearrangement of the 
myeloid/lymphoid leukemia (MLL) gene with various partners occurs in approximately 5% 
of adolescent cases and correlates with poor clinical outcomes. In this rearrangement, the 
disruption of the homeobox (HOX) gene family expression also disrupts the self-renewing 
properties of hematopoietic progenitors. Deletion 9p and Del(1)(p32) impacts a large 
percentage of patients, specifically 40% of adolescent patients and 10% of adult patients. 
Although the clinical relevance is not clearly established, there are known functional 
consequences such as the loss of controlled cell proliferation and differentiation 
impairment. These deletions involve the cyclin-dependent kinase inhibitor 2 (CDKN2) and 
SIL-TAL1 genes, respectively.19 
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b. Recurrent Mutations in T-ALL 
There are numerous mutations that occur in T-ALL that can be delineated by their 
functional consequence. Mutational consequences include impairment in differentiation 
and proliferation, ribosomal activity impairment, altered tumor suppressor function, and 
perturbed signaling regulation. Mutations in NOTCH1(9q34.3), F-box/WD repeat-
containing protein 7 (FBW7(4q31.3)) and B cell CLL/lymphoma 11 B (BCL11B(14q32.2)) 
result in differentiation impairment, loss of cell proliferation control, and aberrant self-
renewal activity. Both FBW7 and BCL11B mutations affect approximately 10% of 
adolescent patients, while FBW7 mutations alone impact 10-20% of adults. NOTCH1 
mutations occur most frequently with an incidence of 60-70% in both adolescent and adult 
patients. Fortunately, there is an overall favorable outcome for patients harboring this 
mutation. In 8% of adolescent patients there are mutations in the ribosomal protein L (RPL) 
genes, specifically RPL5(1p22.1) and RPL10(Xq28) that impair ribosomal activity. While 
they possess no clinical impact, mutations in plant homeodomain like finger 6 
(PHF6(Zq26.3)) and CCR4-NOT transcription complex subunit 3 (CNOT3(19q13.4)) have 
raised suspicion of potentially functioning as putative tumor suppressor genes. Patients that 
harbor mutations in janus kinase 1 (JAK1(1p32.3-p31.3)) have unfavorable outcomes as 
cytokine growth independence, resistance to dexamethasone-induced apoptosis, and JAK 
signaling activation are impacted. Fortunately, this mutation is only found in 2% of 
adolescent patients and 7-18% of adults. Occurring solely in adolescent patients, mutations 
in protein tyrosine phosphatase non-receptor 2 (PTPN2(18p11.3-p11.2)) lead to the 
negative regulation of tyrosine kinases. The functional consequence of increased 
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dephosphorylation of nucleoside analogs has been identified only upon relapse, in 19% of 
relapsed adolescent and adult T-ALL cases as a result of a mutation in 5’-nucleotidase, 
cytosolic II  (NT5C2(10q24.32)).19 
 
c. Novel Subgroups in T-ALL 
A novel subgroup that has been identified in T-ALL is the early T-lineage 
progenitor (ETP) subtype, which incurs a block at the earliest stages of T cell 
differentiation causing them to become CD4-CD8- cells. ETP T-ALL accounts for nearly 
10% of pediatric T-ALL cases and increases in incidence with age as adults with ETP T-
ALL account for 40-50% of adult T-ALL cases.20 At the outset, patients presenting with 
ETP T-ALL were described as high-risk. It was observed that the increased incidences of 
ETP T-ALL were correlated with failure to achieve complete hematological remission, 
higher relapse, and significantly reduced overall survival in pediatric and adult patients.20, 
21 However, recent clinical studies have seen the obliteration of dismal outcomes, 
especially in the instances of pediatric cases with intensified treatment strategies that hold 
their origin in T-ALL standard-of-care (SOC).22   
ETP T-ALL’s transcriptional program is related to early T-lineage progenitor cells 
and is very closely associated with that of HSCs and myeloid progenitor cells.21, 20 
Genetically, ETP T-ALL presents with a lower prevalence of NOTCH1 mutations (around 
25% of incidences) and rarely has CDKN2A deletions. However, ETP T-ALL is 
characteristically associated with mutations in genes that encode signaling proteins (ex: 
neuroblastoma RAS viral oncogene homolog (NRAS), fms related tyrosine kinase 3 (FLT3) 
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and epigenetic regulators (e.g., isocitrate dehydrogenase 1 (IDH1), DNA methyltransferase 
3A (DNMT3A)).20, 23 Moreover, ETP T-ALL is associated with mutations that disrupt the 
activity of transcription factors governing hematopoietic and T cell differentiation (e.g., 
runt related transcription factor 1 (RUNX1), GATA binding protein 3 (GATA3), ETS 
variant 6 (ETV6)). 20, 23  
 T-ALL patients that present with a CD1a+CD4+CD8+ immunophenotype 
experience thymocyte arrest at the early stages of cortical thymocyte maturation and have 
particularly poor prognoses.24 Moreover, this immunophenotype is associated with 
activation in TLX1, TLX3, NKX2-1, and NKX2-2 homeobox genes. These patients have the 
highest prevalence of NOTCH1 mutations and almost universally harbor deletions of the 
CDKN2A locus.15, 25 To the contrary, T-ALL patients who harbor the mature late cortical 
immunophenotype (CD4+CD8+ CD3+) primarily show an activation of the TAL1 
oncogene.15 
 
4. Oncogenic NOTCH1 in T-ALL 
Activating mutations in the key regulator of T cell fate, NOTCH1, affect over 60% 
of adolescent and adult cases of T-ALL.26, 27 NOTCH1, along with the NOTCH (1-4) 
protein family,  is the gene that encodes for a transmembrane receptor with a regulatory 
role in T cell development. Specifically, NOTCH1 influences the commitment of 
hematologic progenitors to the T cell lineage.28, 29  	  
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a. The Role of NOTCH Signaling in T Cell Commitment 
NOTCH is a master regulator of cell processes ranging from differentiation and 
proliferation to apoptosis, adhesion and spatial development. NOTCH is a transmembrane 
glycoprotein that functions as a ligand-activated transcription factor, transducing 
extracellular signals at the cell membrane into transcriptional changes for specific target 
genes in the nucleus.30 Extracellular NOTCH contains multiple epidermal growth factor 
(EGF) repeats that bind its ligands: delta-like-ligand and Jagged. Extracellular NOTCH is 
cleaved by a disintegrin and metalloproteinase, while ϒ secretase complexes cleave 
intracellular NOTCH. It is the cleavage of intracellular NOTCH that results in the 
translocation of NOTCH to the nucleus. Once in the nucleus, by aid of the transcriptional 
repressor CSL (CBFI/suppressor of hairless/lag), co-activator proteins for the transcription 
of NOTCH target genes can be recruited.31, 32 
Notably, in most instances of T-ALL NOTCH1 is not activated by chromosomal 
translocations (t(7;9)(q34;q34.3)), but rather its activation is the result of mutations that 
disrupt specific domains responsible for the controlling of initiation and termination of 
NOTCH1 signaling.29 This truncated, constitutively active form of NOTCH1 can transform 
T cell progenitors.33 Specifically, NOTCH1 signaling is an essential regulator of αβTCR+ 
versus ϒδTCR+ and CD4+ versus CD8+ in the commitment process of T cell lineages.34 
Genetic models involving the overexpression of active, intracellular NOTCH1 resulted in 
the ectopic development of pre-T cells in bone marrow, while the deletion of NOTCH1 in 
HSCs led to a total inhibition of T cell differentiation and thymic atrophy.35,36 Thus, within 
the hematopoietic system, the activation of the NOTCH1 receptor in the thymus is critical 
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for early T cell fate specification and development.  
 
b. Targets of NOTCH1 in T-ALL 
 The elucidation of the oncogenic pathways controlled by aberrant NOTCH1 
activation in T-ALL began by analysis of NOTCH1 direct target genes and regulated gene 
expression profiles. These analyses revealed that NOTCH1 may promote leukemic cell 
growth through the direct transcriptional upregulation of anabolic pathways like nucleotide 
and amino acid metabolism, ribosome biosynthesis and protein translation.37, 38 Moreover, 
genome-wide mapping of NOTCH1 DNA binding sites found a major role for super 
enhancers in the dynamic regulation of NOTCH1 target genes.39  
Hairy and enhancer of split I homologue (HESI), is an evolutionary conserved 
transcriptional repressor that also functions downstream of NOTCH1.40 HESI plays a 
particularly important part in T cell development and NOTCH1-induced leukemogenesis. 
Moreover, NOTCH1 is implicated in activation of phosphatidylinositol 3 kinase (PI3K) 
and nuclear factor kappa-light-chain-enhancer of activated B cells(NF-κB) pathways that 
function downstream of NOTCH1 in the negative regulation of glucocorticoid receptor 
expression.41, 42 Additionally, NOTCH1 suppresses apoptosis via the transcriptional 
downregulation of B-cell lymphoma 2 (BCL2) binding component 3.43 NOTCH1 has also 
been shown to regulate the expression of numerous non-coding elements, for example, 
insulin like growth factor 1 receptor (IGF1R) which  is required for efficient leukemia cell 
growth.44  
An oncogenic role of NOTCH1 in T-ALL is readily demonstrated by the rapid 
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development of acute leukemia in mouse models. In these models, mice were transplanted 
with hematopoietic progenitors that had been infected with retroviruses driving the 
expression of a constitutively active form of intracellular NOTCH1.45, 46 
Moreover, in transgenic zebrafish models of T-ALL the expression of NOTCH1 
induced extensive invasion and aggressive neoplastic cells.47 In pursuit of the identification 
of signaling pathways and genes that are regulated by oncogenic NOTCH1 in T-ALL, 
MYC was identified as a direct target in both T-ALL and breast cancer.37,48 Genetic array 
and chromatin immunoprecipitation experiments revealed that the MYC promoter indeed 
contains NOTCH1 binding sites that are important for the induction of MYC expression in 
T-ALL cell lines.38, 49 
 
c. NOTCH1 Regulation of MYC 
Under normal conditions, MYC expression is highly regulated by a number of 
tightly controlled mechanisms involving the transcriptional regulatory motifs found within 
its proximal promoter region. In fact, in most experimental models of MYC -induced 
tumorigenesis, ongoing MYC activity is required for tumor maintenance and its 
downregulation results in the loss of the malignant phenotype via apoptosis or 
differentiation/senescence. The identification of a long-range, distal NOTCH1 controlled 
MYC enhancer, has formally established a direct role for NOTCH1 in MYC expression.50, 
51 The cell growth promoting effects of the NOTCH1 transcriptional program are enhanced 
by the upregulation of the MYC oncogene. Moreover, both NOTCH1 and MYC share 
many direct target genes.37, 50, 51 
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MYC is a transcription factor and master regulator of cell growth and proliferation 
that is broadly involved in the pathogenesis of human cancer.52, 53 In early T cell 
development  MYC plays an important part in the control of cell growth downstream of 
NOTCH and pre-TCR signaling.54 This mediated regulation of  MYC was found to be 
crucial for T cell development and the initiation and maintenance of NOTCH1 induced T-
ALL in mice.50 Thus, MYC drives cell growth and proliferation in T-ALL, but it also has 
an important role as a driver of leukemia-initiating activity. 
The MYC proto-oncogene is one of the most frequently activated oncogenes. MYC 
directly increases protein synthesis rates by controlling the expression of multiple 
components of the protein synthetic machinery.55 Evidence suggests that MYC oncogenic 
signaling may monopolize translational machinery to elicit cooperative effects on cell 
growth, cell cycle progression and genomic instability as a mechanism for cancer initiation. 
Notably, MYC requires other genetic or epigenetic alterations in vivo to enable its 
tumorigenic potential, as evidenced by a predictable time delay before the onset of 
tumors.56, 57 
Downstream MYC target genes include those encoding translation elongation 
factors, translation initiation factors, nucleolar assembly components, and ribosomal 
proteins that belong to both large and small subunits. The ability of MYC to regulate the 
transcription of several components of the protein synthesis machinery has been validated 
in several different cell types and expression changes correlate proportionately with both 
loss-of and gain-of-function MYC models. 53, 58, 59  Similarly, the effect of MYC in 
stimulating protein synthesis is supported by a direct role of MYC promoting ribosome 
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biogenesis, Notably, the overexpression of MYC results in a substantial increase in the size 
of the cell nucleoli.59, 60 The profound role of MYC in the initiation, progression, and 
regulation of tumor-associated transcriptional machinery endows therapeutic targeting of 
MYC with urgency. At the same time the multitude of implicated roles for MYC regulation 
predict and with recent experimental evidence suggest, targeting MYC is associated with 
gross cytotoxicity. These realities drive us to look at downstream targets of MYC that could 
have just as consequential therapeutic potential with reduced cytotoxicities. 
 
5. Current and Future Therapeutic Strategies of T-ALL 
a. Prognostic Factors 
 The pathogenesis of T-ALL involves the abnormal proliferation and differentiation 
of a clonal population of lymphoid cells. In the adolescent patient population there are 
some genetic syndromes that predispose a minority of patients to    T-ALL. These genetic 
conditions include: Down syndrome, Fanconi anemia, Bloom syndrome, ataxia 
telangiectasia, and Nijmegen breakage syndrome.61, 62 Other predisposing factors are both 
of environmental and health concern, such as exposure to ionizing radiation, pesticides, 
certain solvents and viruses like the Epstein-Barr virus, and Human immunodeficiency 
virus.63, 64 The majority of cases are de novo malignancies in previously healthy individuals 
that present with a hallmark of T-ALL, chromosomal aberrations. However, these 
aberrations are not sufficient enough to generate leukemia. Rather the clinical 
manifestation of T-ALL is the result of an accumulation of malignant, poorly differentiated 
lymphoid cells within bone marrow, peripheral blood, and extra-medullary sites.65, 66 
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A diagnosis is established by the presentation of 20% or more lymphoblasts in bone 
marrow or peripheral blood. Following this pathology evaluation, a patient will receive a 
morphology evaluation, flow cytometry analysis of blood cell populations, 
immunophenotyping, and cytogenetic testing for confirmation. To further determine a 
patient’s risk stratification, lumbar punctures and cerebral spinal fluid analyses are carried 
out. Although the presentation of T-ALL can be non-specific, there is a combination of 
constitutional symptoms patients clinically present with: elevated white blood cell counts 
and hematopoietic failure manifested as neutropenia, anemia, and thrombosis. Moreover, 
patients are found to present with mediastinal thymic masses, extramedullary site 
involvement, and in 5-8% of cases, meningismus infiltration of the CNS.65 
 Patient stratification begins by considering the age and the white blood cell count 
at the time of diagnosis. Increasing age is correlated with a worsening prognosis, with 
patients over 60 years having a particularly poor outcome. In fact, only 10-15% of these 
patients will achieve long-term survival. Age is also a partial surrogate for other prognostic 
factors. Reality holds that elderly patients have intrinsically unfavorable biology, enhanced 
medical comorbidities, and a heightened inability to tolerate standard chemotherapeutic 
regimes.67  
Changes in cytogenetic profiles also have a significant role in the stratification of 
patients. The cytogenetic aberration with the greatest guiding impact on patient 
stratification and treatment is the presence of the Philadelphia chromosome t(9;22). There 
is a prevalence of 15-50% of Philadelphia positivity (Ph+) in adults with T-ALL and the 
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incidence increases with age. Notably, Ph+ is usually associated with a one-year survival 
rate of 10%.68 
 
b. Established Treatments in T-ALL 
Combination chemotherapeutic regimens were first used in T-ALL patients that 
were recognized as a high-risk leukemia group. This first attempt at combination 
chemotherapeutics was said to result in cure rates of approximately 10% for those with T-
ALL. These poor, initial results spearheaded efforts to develop and introduce intensified 
chemotherapeutic protocols, which saw gradual improvement in outcomes. Current cure 
rates in multi-center trials  are around 80% in adolescent and 60% in adult patients.69, 70 
However, despite these promising cure rates, the prognosis of patients with primary 
resistant T-ALL who fail to obtain complete hematological remission or those whom have 
disease relapse after a transient initial response remain poor.71 In T-ALL in particular, 
leukemia relapse is especially challenging as it is associated with secondary chemotherapy 
resistance and a dismal prognosis even in the face of intensified and salvaged 
chemotherapy. During remission, approximately 20% of adolescent and 50% of adults fail 
to undergo complete remission and subsequently die as a result of disease progression.72, 
73  
A patient’s response to their initial therapy historically predicts their outcome.74 As 
mentioned, risk stratification by age places adolescent and young adults (age 15-39 years) 
into treatment cohorts that benefit from pediatric-inspired regimens and are considered 
separate from adults, those greater than 40 years.65 SOC chemotherapy consists of an 
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induction, consolidation/intensification, and a long term maintenance phase. Those with 
central nervous prophylaxis are given specific therapeutic interventions at different 
intervals throughout their treatment. 
In the induction phase, the goal is to eradicate more than 99% of the initial leukemic 
cell burden and restore normal hematopoiesis to a healthy performance status. Induction 
includes the administration of a glucocorticoid, vincristine, and at least a third drug like an 
asparaginase, anthracycline or both. A three-drug induction regimen is sufficient in most 
cases, but must be intensified if it is used in post-remission treatment. There is not a clearly 
superior induction regimen, but the addition of cyclophosphamide and intensive treatment 
with asparaginase has been proven to be beneficial. The largest complication to be weary 
of in the induction phase of treatment is a synergism between the corticosteroid and 
asparaginase in the context of multi-agent treatment.75, 76  
Larson et. al. conducted one of the first group B clinical trials using a four-week 
induction schedule. In this protocol, cyclophosphamide on day one, three, and consecutive 
days of daunorubicin, weekly vincristine, bi-weekly L-asparaginase, and three weeks of 
prednisone were administered. This protocol resulted in a complete response rate of 85% 
and a median survival of 36 months.77 In patients over 60 years of age, the same protocol 
was followed but with a dose reduction of one-third.78 Those patients that presented with 
central nervous prophylaxis were also given methotrexate, cytarabine, oral 6-
mercaptopurine, and cranial radiation.79 This induction cycle was followed by three 
consolidation/intensification cycles. If patients were especially high risk and there was a 
matched bone marrow donor, patients were urged to receive allogeneic-stem cell therapy 
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(allo-SCT).80 
The goals of the consolidation/intensification treatment phase are to eradicate drug 
resistant residual leukemia cells and reduce the risk of relapse. A consensus is scarce on 
the best regimens and duration of treatment, but in general this phase utilizes the same 
chemotherapeutic agents in induction but includes intrathecal chemotherapy. There are 
some frequently used strategies that focus on high dose methotrexate and mercaptopurine 
with initial, frequent pulses for 20-30 weeks. The long-term maintenance phase is used to 
prevent or offset all relapse. Maintenance therapy consists of daily          6-mercaptopurine, 
weekly methotrexate and vincristine, and a five-day prednisone pulse every three months. 
This maintenance therapy protocol is administered for two-three years post-induction. 
Notably, it has been found that there is no benefit beyond these two-three years.66, 80  	  
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Figure 1.2. Graphic representation of the risk-oriented T-ALL therapy standard-of-care. 
 
c. Refractory and Relapsed Disease 
Fortunately, 85-90% of patients go into remission after induction therapy, while the 
remaining are refractory to induction therapy. Unfortunately, the majority of patients that 
do achieve complete remission will go onto relapse. For those patients that do not have the 
Philadelphia chromosome translocation, the options for relapsed/refractory (r/r) salvage 
therapy include augmented cytotoxic chemotherapy, reformulated single-agent 
chemotherapy, and novel monoclonal antibodies. Multi-agent, cytotoxic chemotherapy can 
only modestly prolong survival. Long-term survival has only been found in patients that 
receive allo-SCT therapy. Promisingly, novel monoclonal antibodies have transformed the 
landscape of salvage therapy and demonstrated a future with long term cures devoid of 
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reliance on allo-SCT treatments.81 
The best characterized monoclonal antibody is a bispecific anti-T cell receptor/anti-
CD19 antibody, blinatumomab. Blinatumomab engages T cells to activate B cell specific 
inflammatory and cytolytic responses with an acceptable toxicity profile and few adverse 
events. Blinatumomab serves as a frontline therapy for B-ALL, but is not amenable for T-
ALL salvage therapy.82, 83 An alternative option that is FDA approved and actively being 
used for r/r T-ALL is Nelarabine. In T-ALL this purine nucleoside analog accumulates in 
T cells at a high rate and incorporates into DNA, leading to an inhibition of DNA synthesis 
and subsequent apoptosis. There is much more that needs to be done to elicit better response 
rates and overall survival in patients with r/r T-ALL, driving our research in pursuit of not 
only better formulated future therapies, but better characterized targeted future therapies.84 
 
d. Future Therapeutic Approaches 
i. Monoclonal Antibodies 
Monoclonal antibodies are in development to target CD22, CD20, CD19 and CD25. 
Upon binding of an antibody, CD22 is rapidly internalized making it an attractive target 
for delivering immunity into leukemia cells.85, 86 Epratuzumab is an unconjugated 
monoclonal antibody that has been studied in pediatric and adult r/r ALL. When evaluated 
as a salvage therapy, wherein Epratuzumab is administered as a single agent followed by 
re-induction chemotherapy, it demonstrated a superior response rate.87 Another 
monoclonal antibody directed towards CD22 is Inotuzumab ozogamicin (Ino). Ino is 
conjugated to calicheamicin, a potent cytotoxic compound that induces double-strand DNA 
	21	
breaks and apoptosis.88 Preclinical studies have demonstrated a potent cytotoxicity of Ino 
that leads to the regression of B cell lymphoma and additionally prevents the establishment 
of xenografts at picomolar concentrations.89 Phase II clinical studies have shown that both 
progression free survival and overall survival are prolonged with Ino compared to the 
current standard of care.90 Finally, Moxetumomab pasudotox is a CD22 monoclonal 
antibody in development for the treatment of adolescent and adult ALL. This antibody is a 
reformulation of an older study drug BL22, that has an overall efficacy rate of 70% in 
children with r/r ALL in an ongoing phase I/II trial.91 
CD20 is a B lineage specific antigen that is expressed at nearly all stages of 
differentiation on the surface of both normal and malignant B cells. Signaling through 
CD20 involves cell-cycle progression, differentiation pathways, and regulation of 
apoptosis. CD20 is expressed in 40-50% of precursor lymphoblasts and confers a poor 
prognosis, as  patients with CD20 expression respond poorly to dose intensification.92  
Ofatumumab  induces high levels of complement-dependent cytotoxicity and a slower 
dissociation rate leading to great efficacy for CD20+ lymphoid malignancies as a frontline 
therapy.93, 94, 95 Finally, REGN1979 is a biallelic monoclonal antibody that targets both 
CD20 and CD3. This antibody engages T and B cells, resulting in the activation of a T cell 
immune response against B cells. REGN1979 is also shown to prevent the establishment 
of lymphoma in xenograft mouse models leading to complete tumor regression.96 
In approximately 30% of pre-B-ALL lymphomas, including 100% of the Ph+ 
patients, the cell surface antigen CD25 is expressed. CD25 is a component of the 
interleukin-2 receptor (IL-2) heterotrimer. The IL-2 signaling pathway is particularly active 
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in the T cell immunoresponse and has thus been an attractive therapeutic target for post-
transplant immunosuppression. ADCT-301 is a conjugated CD25 antibody that is shown 
to be cytotoxic to CD25+ anaplastic large cell lymphoma and Hodgkin lymphoma cell 
lines. This positive result has moved ADCT-301 into phase I trials for r/r AML and ALL.97 
 
ii. Proteasome Inhibitors 
Beyond monoclonal antibodies, there are numerous other therapeutic moieties 
being developed and modified for use in ALL. Bortezomib is a well-known proteasome 
inhibitor that was first approved for treatment in multiple myeloma. Because of its known 
ability to inhibit NF-κB and NOTCH1 signaling pathways, there is interest in using 
bortezomib as a frontline therapy. Preclinical combinatory trials that utilized bortezomib 
and dexamethasone showed additive effects with standard ALL chemotherapeutic 
practices.98 In combination with vincristine, dexamethasone, PEGylated asparaginase, and 
doxorubicin, treatment with bortezomib elicited an 80% response rate in adolescent r/r pre-
B-ALL phase II trials. Notably, a durable response was not observed in r/r T- and B-ALL 
when bortezomib was used as a single agent despite its demonstrable proteasomal 
inhibition.99, 100 
 
iii. JAK Inhibitors, PI3K/mTOR Inhibitors, and Hypomethylating Agents 
The JAK/Stat pathway is utilized by leukemic cells to bypass normal growth and 
proliferation restrictions.101 The JAK inhibitor, ruxolitinib, is in preclinical studies that 
show benefits for clinically presenting Philadelphia-like ALL and type I cytokine receptor 
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(CRLF2-ALL) patients.102, 103 The PI3K and mammalian target of rapamycin (mTOR) 
pathways are shown to be constitutively active in 50-75% of T-ALL. Preclinical studies 
have shown that the inhibition of this pathway, with both PI3k and AKT inhibitors may be 
effective in T-ALL treatment.104, 105 DNA methylation is another important modification  
that regulates gene expression. It has long been reported that DNA methylation may play 
a role in the development of ALL making hypomethylating agents of great interest.106, 107 
Hypomethylation of key DNA regulatory domains leads to differentiation and suppression 
of tumor growth. Additionally, methylation status has the potential to be used in risk 
stratification.108, 109 Clinically, decitabine, a cytosine analog that works to inhibit DNA 
methyltransferase by targeting it for degradation is receiving therapeutic prioritization. 
Administered as a monotherapy it is well tolerated and offers a potential treatment option 
for relapsed disease in patients that cannot tolerate multi-agent therapies. Moreover, in 
early T cell precursor ALL, decitabine is shown to synergize with conventional therapy.110 
 
6. Conclusions 
 T-ALL is believed to be derived from malignant thymocytes that arise at defined 
stages of intrathymic T cell differentiation. Despite the aggressive nature of this 
hematologic malignancy, the long-term survival of standard risk T-ALL patients is 
approaching 90% for adolescents. However, the disease free survival rates are much more 
modest in adult patients on SOC treatments owing to the complexity and gross cytotoxic 
effects of these multi-agent protocols.  In order to overcome these clinical challenges 
efforts must be, and are being made to decipher the molecular events underlying T-ALL 
	24	
transformation. As such, genomic studies have started to uncover the genetic basis of 
leukemia relapse and have indicated a selection of genetic variants in clonal evolution that 
drive chemotherapeutic resistance and disease progression. My research utilizes these 
translational methods to characterize the molecular and functional roles of a novel target 
in leukemogenesis to bring to light the implications of targeted therapeutic intervention in 
T-ALL. 
 
B. The Endoplasmic Reticulum Stress Response Pathways 
1. Introduction 
The endoplasmic reticulum (ER) is the major site of protein folding and assembly 
in the secretory pathways. The ER is an extensive 3D cellular network of interlinked 
membranous tubules, sacs, and flattened cisternae that spans the nuclear envelope and 
secretory vesicles. The ER participates in a variety of cellular functions like the synthesis 
and sorting of secretory and membrane proteins, biosynthesis of phospholipids, 
cholesterol, steroids, degradation of glycogen, detoxification reactions, and maintenance 
of intracellular calcium homeostasis.111, 112  Eukaryotic cells have evolved a highly 
conserved ER quality control system that both catalyzes protein folding and prevents 
unfolded polypeptides or unassembled protein complexes from reaching their final 
destinations. Misfolded or unfolded proteins that are unable to assemble into their native 
conformation in the ER are retrotranslocated into the cytosol where they are subsequently 
degraded by the proteasome. 
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2. An Overview of the Endoplasmic Reticulum (ER) Quality Control Mechanisms 
a. The Unfolded Protein Response (UPR) 
The UPR is one of the early responses to ER stress. The UPR is initiated by the 
three transmembrane receptors: PKR-like ER kinase (PERK), activating transcription 
factor 6 (ATF6), and inositol-requiring enzyme 1 (IRE1). These transmembrane receptors 
sense the accumulation of unfolded proteins and their activation can trigger specific 
adaptive responses to resolve stress.113 The same receptors can also initiate signaling 
pathways that lead to apoptosis when attempts to resolve ER stress fail. The process of 
protein folding within the ER is executed by folding and oxidizing enzymes, aided by 
chaperones and glycosylating enzymes that require high Ca2+ levels typically present inside 
the ER lumen, as well as large stores of adenosine tri-phosphate (ATP), and an oxidizing 
environment.111 Inherently, the correct folding of nascent polypeptide chains is dependent 
on amino acid sequence, such that certain mutations in the sequence can lead to misfolding 
and aggregation.  
The sensitive nature of the folding process in the ER represents a read out of the 
metabolic and functional status of a cell. The ER harbors mechanisms transducing this 
information to the cytoplasm and nucleus to either restore folding or promote apoptosis.114 
In resting cells the ER transmembrane receptors are associated with the immunoglobulin 
binding protein (BiP), keeping them inactive. Under ER stress, to deal with increased 
protein accumulation, BiP dissociates from the three sensors leading to their activation.115, 
116 This UPR activation is the defining criteria of ER stress. The UPR initially promotes 
cellular repair and survival through reducing the load of unfolded proteins via the 
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attenuation of protein synthesis, induction of molecular chaperones, activation of 
endoplasmic reticulum associated degradation (ERAD), and cell-cycle arrest in the G1 
phase.114 
 
i. The UPR-Mediated Mechanisms of Adaptation to ER Stress 
One UPR mediated mechanisms to adaption of stress is through PERK activation. 
PERK is an ER transmembrane kinase that phosphorylates eukaryotic initiation factor 2α 
(eIF2α). This phosphorylation blocks the initiation of protein translation and attenuation of 
protein synthesis, reducing the protein load in the ER.117 Short lived proteins, such as cyclin 
D1, decay rapidly under these conditions inducing cell cycle arrest and thus allowing time 
for the cell to recover.118 Although general translation initiation is inhibited, translation of 
certain transcripts is increased. For example, translation of the main open reading frame 
(ORF) is typically prevented by preceding short upstream ORFs that can be bypassed under 
conditions of slowed translation initiation.119, 120 Through this mechanism ATF4 (A 
transcription factor 4) is upregulated. This upregulation induces a set of genes involved in 
amino acid metabolism, antioxidant stress response, and protein secretion to maintain ER 
homeostasis.121, 122 ATF4 also induces a second transcription factor C/EBP-homologous 
protein (CHOP), which is involved in mediating homeostasis through the upregulation of 
growth arrest and DNA damage-inducible protein (GADD34).121, 123 GADD34 is an 
activator of protein phosphatase 1 (PP1) which dephosphorylates phospho-eIF2α.124, 125 
This promotes recovery from translational repression helping cells resume normal 
function.126, 127 The second PERK target is nuclear related factor 2 (NRF2). Normally, 
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NRF2 is targeted for ubiquitin-mediated degradation by interaction with the protein Kelch-
like ECH-associated protein 1 (KEAP1). When KEAP is modified by oxidizing agents, 
NRF2 is liberated and translocates to the nucleus where it activates genes encoding 
antioxidant proteins. Contrarily, NRF2-deficient cells display enhanced apoptosis during 
ER stress.128, 129 
A second ER stress sensor, ATF6, has two isoforms of either α and β that become 
active during ER stress through the same mechanism.130 ATF6α, denoted as ATF6 
hereafter, plays the main role in the UPR. Once BiP has dissociated from its luminal 
domain, ATF6 is transported to the golgi apparatus where it becomes proteolytically 
cleaved from its membrane anchor.131, 132 The released form of ATF6 translocates to the 
nucleus to activate genes. To activate genes, ATF6 binds to promoters containing the ER 
stress response elements. This binding transactivates ER stress induced genes, mainly 
encoding ER chaperones and proteins involved in ERAD,130 helping cells cope with 
accumulating unfolded proteins.133, 134  ATF6 can also induce the gene of another 
transcription factor, x box-binding protein 1 (XBP1) which is similarly important for cell 
survival during ER stress.135 
The third ER stress sensor, IRE1, also has two isoforms (α and β). IRE1β is found 
in the intestine, while IRE1α is the more commonly expressed amongst tissues. IRE1α is a 
bifunctional molecule that harbors a kinase domain and a C terminal RNase domain in its 
cytoplasmic moiety.136 The activation of IRE1α  leads to the oligomerization and trans-
autophosphorylation of its kinase domains.125, 137 The main homeostatic signaling output 
emanates from the RNase domain, which specifically removes an intron from the 
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unspliced, full length XBP1 mRNA to generate spliced XBP1.138 Spliced XBP1 is a highly 
active transcription factor and a key regulator of the ER folding capacity as it activates 
genes that enhance the degradation of misfolded ER proteins.139 IRE1α signaling through 
XBP1 splicing is essential for active secretory cells whose reticular protein-folding 
machinery is continuously engaged with a high amount of nascent proteins.140, 141 The 
prolongation of IRE1α signaling during ER stress can promote cell survival, serving as an 
important adaptive mechanism to match the ER folding capacity with demand.142 
 
ii. The UPR-Mediated Signaling in Cell Death 
Signaling from the UPR can shift from an adaptive response to promoting cell death 
under prolonged periods of ER stress activation. Caspase activation predominantly occurs 
through the mitochondrial intrinsic pathway promoting crosstalk between the ER and 
mitochondria. One cell death signaling cascade may begin with the release of Ca2+  from 
the ER.143 There is also the possibility that the tyrosine kinase C-ABL could transduce a 
signal from the stressed ER to mitochondria to induce apoptosis.144 Each of the 
aforementioned transducers has been demonstrated to either directly or indirectly modulate 
proteins of BCL2 family to promote mitochondrial outer membrane permeabilization. This 
permeabilization induces the intrinsic pathway of caspase activation and apoptosis. 
The phosphorylation of eIF2α has also been implicated in the activation of 
apoptosis.  The major pro-apoptotic consequence of eIF2α phosphorylation is the 
upregulation of the transcription factor CHOP mediated by ATF4. CHOP target genes 
implicated in ER stress induced apoptosis include, members of the BCL2 family, GADD34 
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(which may lead to expression of proapoptotic proteins), pseudo kinase tribbles-related 3 
(TRB3) and ER oxidase-1-α (ERO1α).145 Initially, CHOP downregulates the transcription 
of anti-apoptotic BCL2 and transcriptionally upregulates expression of pro-apoptotic 
protein BIM (BCL2 like 11 protein).146 The translocation of BIM to the cytosolic face of 
the ER leads to the activation of the death signaling cascade.147 
In cancer cell lines, CHOP also mediates upregulation of the pro-apoptotic death 
receptor (DRS), sensitizing cells to apoptosis during ER stress.148 Accordingly, TRB3 and 
CHOP form a complex leading to the impaired transactivation of target genes. Precisely 
how this complex leads to apoptosis remains unclear, it’s postulated that it may be related 
to the inhibition of AKT (RAC-alpha serine/threonine) kinases.149 Increases in ERO1α, 
which normally contribute in supporting an oxidative environment, crucial for disulphide 
bond formation in the ER, can lead to the hyperoxidation of the ER lumen inducing 
oxidative stress and promoting apoptosis via calmodulin kinase II (CaMKII).122, 124  
It was long thought that ATF6 solely fulfilled an adaptive function. However, it has 
been recently shown to indirectly downregulate the anti-apoptotic BCL2 family member 
MCL-1 (myeloid cell leukemia sequence 1) in a myoblast cell line, demonstrating its 
potential role in triggering apoptosis. Additionally, it has been observed that IRE1α 
signaling is turned off under conditions of prolonged ER stress, while PERK signaling 
remains active under a cell’s demise.150 However, a new mechanistic link has demonstrated 
that IRE1α associates with tumor necrosis factor receptor-associated factor 2 (TRAF2). 
This association promotes the cascade of phosphorylation events involving mitogen-
activated protein kinase apoptosis signal-regulated kinase 1 (MAP3K-ASK1) culminating 
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in c-JUN N terminal kinase (JNK) activation. JNK is a key regulator of many cellular 
events and has a pro- or anti-apoptotic function depending on the cell type, nature of death 
stimulus, and duration of its activation. During ER stress, sustained JNK activation is 
thought to promote apoptosis by modulating the activity of BCL2 family members.151, 152 
The phosphorylation of BCL2 and B cell lymphoma-extra-large (BCLxL) by JNK can 
suppress anti-apoptotic activity.153 Precisely how UPR signaling switches from adaptive to 
pro-apoptotic signaling is largely unknown, but will be essential in the development of 
drugs to treat ER stress related diseases.114  
Autophagy can also reduce ER stress, especially under the threat of protein 
aggregation. ER stress induced autophagy is initiated when portions of the ER, proteins, 
and protein aggregates are engulfed in autophagosomes and delivered to the lysosomes or 
vacuole for degradation. ER stress unresolved through autophagy subsequently promotes 
an apoptotic response.154  
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Figure 1.3. The three stress transducers of the unfolded protein response. 
PKR-like ER kinase (PERK), activating transcription factor 6 (ATF6), and inositol-requiring enzyme 1 
(IRE1) are the three stress transducers activated in the UPR. The relevant transcription factors for specific 
adaptive or cytotoxic responses to resolve stress are mapped. 
 
b. Endoplasmic Reticulum Associated Degradation (ERAD) 
Approximately one-third of all proteins in eukaryotes are targeted to the secretory 
pathway. The first compartment encountered by this diverse substrate ensemble is the 
ER.155 The ER contains molecular chaperones that assist in protein folding and also 
contains unique enzymes that maintain an oxidizing environment relative to the cytoplasm 
and catalyze co- and post-translational modifications.156 Secreted proteins are subject to 
ER quality control via primary mediators, such as molecular chaperones that not only 
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sample and help polypeptides to fold, but also evaluate the conformation of their substrates. 
Polypeptides that attain their native conformation are then targeted to their final 
destination.157  If delayed folding or illegitimate conformation arises, the substrate is 
subjected to additional folding cycles or selected for ERAD.158 
ERAD is a quality control pathway in which proteins that are either misfolded or 
unfolded in the ER are retrotranslocated to the cytosol and subsequently degraded by the 
proteasome. The process of protein folding is inherently error prone. This is largely due to 
the fact that the folding energy landscape for a polypeptide might include several, non-
native intermediate states.  Additionally, spontaneous errors during transcription and 
translation, genetic mutations, toxic compounds, and cellular stresses such as increased 
temperature and osmotic stress can compromise folding efficiency and/or rate. Moreover, 
the chemical environment in the cell might not match the conditions that are required for 
the efficient folding of a given polypeptide.159  
 
i. Substrate Recognition 
If the concentration of unfolded or misfolded polypeptides becomes too great, 
compensatory pathways are induced. Identified by both genetic and biochemical 
approaches, ERAD recognizes substrates, polyubiquitinates, retrotranslocates, and then 
degrades them by the proteasome. There is increasing evidence that a larger percentage of 
some wild-type proteins are destroyed by the ERAD pathway, but this is a cautionary 
measure for cells to degrade them as the cell cannot afford the risk of toxic aggregates. In 
the process of substrate recognition, potential ERAD substrates can be soluble integral 
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membrane proteins, polypeptides that have failed to become post-translationally modified 
or are otherwise damaged or misfolded, and unassembled members of multiprotein 
complexes.160  
Recognition of substrates is dependent on their classification. Hydrophobic patches 
of ERAD substrates, in their native conformation, are usually buried within the interior of 
soluble proteins in order to maintain the lowest energy state. Exposed hydrophobic patches 
in an unfolded state frequently lead to aggregation. To minimize this aggregation, 
molecular chaperones, most commonly the 70 kDa heat-shock protein members (HSP70) 
bind to short polypeptide motifs with hydrophobic properties. A prolonged interaction 
between an ERAD substrate and an HSP70 might be sufficient to recruit a ubiquitin ligase, 
and once the substrate becomes polyubiquitinated, ERAD can be ensured. BiP and 
sometimes HSP40 family members associate with several ERAD substrates and maintain 
their solubility. To do this, BiP resides in an E3 ubiquitin ligase-containing multiprotein 
complex in the ER membrane. It is currently unclear if this is required for the recognition 
of every ERAD substrate.161  
 The majority of proteins that translocate into the ER are co-translationally modified 
with an N-linked oligosaccharide that after processing results in a glyco-protein containing 
an N-acetylglucosamine mannose moiety. Proteins modified with this sugar moiety are 
competent for ER exit. If instead, a glycoprotein contains hydrophobic patches or is in a 
molten globule-like state, it is recognized by glycoprotein glycosyl-transferase (UGGT). 
The complete mechanism by which UGGT can detect terminal misfolding and target 
substrates for ERAD is still unknown.162, 163  
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The addition of glucose to an N-linked glycol results in monoglucosylated, non-
native species which re-enter the calnexin-calreticulin cycle. The cross-talk between BiP 
and the calnexin-calreticulin cycle allow BiP to readily identify these non-native 
substrates.164 This cross-talk can occur as a sequential interaction,165 synergistic 
interaction166 or a compensatory mechanism in which BiP overcompensates for the absence 
of the calnexin-calreticulin cycle by binding to glycosylated substrates.167 
The ER environment is also ideal for disulphide bond formation as it is more 
oxidizing than the cytoplasm and promotes bond catalyzation by protein disulphide 
isomerases (PDIs). PDIs identified in the ER participate in ERAD of several substrates and 
can also work in tandem with BiP, although the mechanism by which this occurs is not 
resolved.168, 169  
 
ii. Substrate Targeting 
In the process of substrate targeting, soluble ERAD substrates must first be selected 
for retrotranslocation to the cytoplasm as enzymes required for ubiquitination reside in this 
compartment. For ERAD substrates that reside in the ER membrane, ubiquitination 
precedes or occurs concomitant with retrotranslocation. Accumulating evidence suggests 
that the location of a misfolded protein dictates the factors that are required for ERAD 
substrate targeting. Thus, proteins with lesions in the cytoplasmic, luminal and membrane 
shaping domains follow ERAD-C, -L and -M respectively.161, 170 171 172 Thus far, these 
pathways have only been identified in yeast as mammals possess a more elaborate 
repertoire of ERAD-requiring components. It’s possible that distinctions between the 
	35	
pathways may have become blurred as higher eukaryotes evolved a larger number of more 
complex secretory-pathway. Even yeast pathways can overlap as this probably serves to 
increase degradation efficiency and allows the cells to compensate for substrate overload 
in one pathway.170, 173, 174  
 The coupling of recognition and targeting of ERAD substrates may frequently 
occur as it remains unclear whether ERAD substrates are actually passed between distinct 
recognition and targeting complexes. Recent observations suggest that factors required for 
recognition reside within multiprotein complexes that are also essential for targeting. For 
example, in yeast, BiP is tethered to the ER membrane by virtue of its interaction with an 
integral membrane partner, SEC63 translocation protein. SEC63 resides in a multiprotein 
ensemble in the yeast ER175 that includes SEC61; a candidate for the retrotranslocation 
channel.176-177 Beyond SEC61, the Derlin family of proteins are alternative candidates for 
the retrotranslocation channel.178, 179 Moreover, the ER ubiquitin ligases that are required 
for ERAD in yeast, are multispanning membrane proteins and are members of large protein 
complexes that include substrate recognition, targeting and retrotranslocation components. 
Housing the ubiquitination and retrotranslocation activities in a single enzyme might be 
the most efficient way to target ERAD substrates to the proteasome.180  
 
iii. Ubiquitination and Proteasome Degradation 
Ubiquitination is carried out through a series of sequential enzymatic reactions. The 
first enzyme being the ubiquitin activating enzyme (E1), followed by the ubiquitin 
conjugating enzyme (E2), and concluding with the ubiquitin ligase (E3). Ubiquitin (ub) is 
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first covalently conjugated to a reactive cysteine residue of E1 (E1-ub) and is then 
transferred to a catalytic cysteine of E2 (E2-ub). Finally, E3 ligases facilitate the transfer 
of ubiquitin from E2-ub to a lysine residue on the ERAD substrate (or another ubiquitin 
moiety).174, 181, 182 This reaction can be repeated several times to form polyubiquitin chains. 
On occasion, a specialized E3 ubiquitin ligase denoted as an E4 enzyme elongates ubiquitin 
chains of oligoubiquitinated proteins to generate polyubiqutinated conjugates from 
oligoubiquitinated precursors. This may suggest that the polyubiquitin appendage must 
reach a crucial length before a substrate can be retrotranslocated.183  
In tagging proteins for degradation, degradation of alpha 1 (DOA10) and HMG-
CoA HRD1 (3-hydroxy-3 methyglutaryl coenzyme A reductase degradation 1) ligases in 
yeast have been implicated in the degradation of every studied ubiquitinated ERAD 
substrate.184 Both enzymes contain catalytic ring domains and exhibit somewhat unique 
preferences for different E2 ubiquitin conjugating enzymes.185, 186 Mammalian orthologues 
have been identified and unsurprisingly the repertoire of E3s that have been implicated in 
ERAD is greatly expanded in higher organisms. One such E3 is a F-box only protein 2 
(FBXO2) substrate recognition component of a SCF (stem cell factor) E3 complex that 
binds glycosylated substrates.135 There is a great complexity and network of ERAD 
substrates that exists in choosing E3 partners.  
Once polyubiquitinated, substrates are extracted from the membrane prior to or 
during proteasome targeting. The proteasome is sufficient in a few cases to retrotranslocate 
substrates itself.187, 188 In mammals the valosin-containing-protein, p97, complex might be 
recruited to the ER membrane. It is unknown how this p97 complex first sees ERAD 
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substrates, particularly those inside the ER lumen that need access to the cytoplasmic face 
of the ER. It's possible that the p97 complex might transiently embed into the putative 
retrotranslocon then recognize and pull substrates into the cytoplasm. The second 
possibility is that the polyubiquitin moiety on tagged substrates, provides a handle for the 
complex to initiate ATP-dependent extraction.189 It remains unknown whether or not the 
p97 complex is needed for the ERAD of all ubiquitinated ERAD substrate. However, there 
is evidence that the degree of membrane protein embedding in the lipid bilayer may dictate 
the degree of necessary p97 complex function.190, 191 Interestingly, a substantial percentage 
of proteasome complexes reside at the surface of the ER membrane, ideally positioned to 
receive and degrade substrates.192 This begs the question; does an ERAD-dedicated 
population of proteasome exist? 
Deubiquitylation, occurs prior to degradation and is mediated by proteasome 
associated enzymes and integral proteasome subunits. These enzymes catalyze en bloc 
removal of polyubiquitin or the trimming of the chain.193 This process may be essential for 
the substrate to enter the proteasome or provide the substrates a second chance to escape 
degradation. Many of the enzymes in this process have not been identified. In fact only one 
study has shown ataxia-3 as having an involved role.194 
Only properly folded proteins are permitted for transit to their final destination 
through the secretory pathway. Thus, ERAD machinery and recognition must properly read 
the folded state of a protein. It then begs the question, how do proteins that pass quality 
control find their way to specialized ER exit? Recent findings indicate that there is 
competition between protein transport and ERAD selection machinery, suggesting the 
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decision to transport or degrade substrates may also depend on cell type, stress, secretory-
protein load, and/or signaling processes.  
 
c. Interplay Between the UPR and ERAD  
ERAD is constitutively active to cope with the constant production of misfolded 
proteins in the ER. When the load of misfolded proteins increases beyond ERAD capacity 
and ER chaperones are saturated, ER stress ensues leading to the activation of adaptive 
mechanisms through the UPR. The inefficient disposal or overproduction of aberrant 
proteins can compromise ER homeostasis; therefore, ERAD must be regulated, again 
alluding to interplay between ERAD and other pathways. 
Moreover, genes coding for elements of ERAD are upregulated as part of the UPR 
in order to increase the degradative capacity of ERAD. The transcription of a subset of 
factors required for ERAD is induced by the UPR, which is activated through the directed 
interaction of misfolded proteins with a transmembrane sensor in the ER and/or through 
the titration of BiP away from the UPR sensors. Cytoplasmic stress, oxidative stress, and 
heat shock decrease ERAD efficiency.195 Therefore, the UPR induces other factors to 
reduce the ER stress including: expanding the volume of the ER by upregulated lipid 
synthesis, increasing the concentration of molecular chaperones and enzymes required for 
post-translational modifications, decreasing protein translation and ER translocation, and 
upregulating protein transport through the secretory pathway emptying the ER of 
potentially toxic polypeptides, and the cleavage of ER-associated mRNA that encode 
secreted proteins .196 The failure to compensate for ER stress through ERAD and the UPR 
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eventually leads to the triggering of apoptosis. However, cross-pathway communication in 
ERAD remains poorly understood. 
 
3. ER Stress and Malignancy 
 The UPR seems to adjust to the harsh tumor microenvironment as one of the 
resistance mechanisms against cancer therapy. The ER stress response is considered 
cytoprotective and is involved in tumor growth and adaptation against harsh environments. 
In tumor cells, ER stress may restore homeostasis and make the adjacent environment 
hospitable for tumor survival and expansion.197 Hypoxia, nutrient deprivation, pH changes 
or poor vascularization can be growth limiting for tumor cells, thus promoting the tumor 
cells to activate the UPR.  Specifically, the hypoxic bone marrow environment and high 
glucose demands resulting from rapid proliferation contribute to ER stress in leukemia.198, 
199 Moreover, during tumorigenesis, the high proliferation rates of cancer cells require an 
increased activity of ER protein folding, assembly, and transport, which are conditions that 
can also induce physiological ER stress.200, 201  
BiP, ER chaperones, and UPR components are overexpressed in several tumor 
types. In particular, IRE1α and XBP1 are found to be increased in many human cancers 
such as breast, hepatocellular carcinoma, and pancreatic adenocarcinoma.202 The PERK-
eIF2α-ATF4 axis is also implicated in cancer progression.203 It’s demonstrated that ATF4 
compensates for an increase in severe hypoxic conditions in human breast cancer tissues204, 
205 and PERK supports beta cell proliferation and promotes angiogenesis in human tumor 
xenograft mice.206 Calreticulin, an ER resident chaperone has been localized to the cell 
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surface in tumor cells.207, 208  
It is postulated that the adaptive response of the UPR enhances tumor growth, while 
the cytotoxic response induces tumor cell apoptosis. Convincingly, the analysis of 
spontaneous mouse and human lymphomas demonstrated significantly higher levels of 
UPR activation compared with normal tissues. Tumor cells continuously divide and thus 
can be challenged by restricted supplies of nutrients, oxygen and decreased vascularization. 
Cancer cells adapt to this microenvironment by activation of UPR providing a window of 
time for the tumor cells to resolve stress and reestablish homeostasis. If this process fails, 
survival signaling is attenuated and death signaling becomes the predominant process.209 
BiP is one of the most active components of cancer cells and is overexpressed in 
different kinds of cancers210, 211 that has recently been implicated in tumorigenesis, 
metastasis, and angiogenesis. As a chaperone protein, BiP may enhance cancer cell 
adaptation against hypoxic environments and function as a resistance protein against anti-
cancer therapy.212, 213 Moreover, BiP regulates cell apoptosis, proliferation, invasion, 
inflammation, and immunity especially in numerous tumor sub-types.214 The 
overexpression of BiP also decreases the sensitivity of glioma cells to etoposide and 
cisplatin.215 In some studies, BiP has been used as an effective biomarker for aggressive 
tumor behavior and correlates with a poor prognosis in cancer.216, 217  
PERK has regulatory roles in tumor initiation and survival, facilitating adaptation 
in microenvironments rich in hypoxia and oxidative stress.197, 200, 218, 219 Tumor cells grow 
rapidly and form new vasculature, linking the microenvironment and nutrient deprivation 
conditions.  Disturbances in production of ATP by glycolysis result in the production of a 
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reducing equivalent and increase the demands of glucose and oxygen. These cytotoxic 
conditions, lead to the generation of reactive oxygen species in mitochondria and can 
activate ER stress. Therein nutrient deficiencies increase ER stress and lead to PERK 
activation. 220, 221   IRE1α also contributes to the maintenance of malignancy under 
oncogenic stress.222, 223 IRE1α regulates cyclin A1 expression and promotes cell 
proliferation by splicing XBP1 in prostate cancer.224 Moreover, high levels of spliced 
XBP1 expression are proportional to increases in tumor survival. Interestingly, increasing 
the concentration on unspliced XBP1 leads to an elevation of apoptosis in tumor cells.225 
A hyperactivation of oncogenes can transform normal cells into malignant states, 
overriding growth arrest or senescence controls at the same time suppressing proapoptotic 
signals.  The oncogenes MYC, RAS, BRAF and mTOR have a confirmed role of UPR 
associated transformation and progression.226 MYC is an oncogene that is essential for 
promoting cancer growth and progression by increasing the rate of protein synthesis, 
ribosomal biogenesis, coordinating between lipogenesis and protein synthesis, maintaining 
mitochondrial function and its biogenesis. In fact, approximately 40% of human cancers 
are associated with its deregulation.53  
Hart et. al.  have demonstrated that by increasing protein load to the ER, MYC 
activates the PERK/ATF4 arm of the UPR, establishing a role for MYC dependent tumor 
transformation and cancer cell proliferation and cytoprotective autophagy to support cell 
viability. A novel cell autonomous mode of activation of the UPR was also found in 
response to increased MYC activity. PERK and eIF2α phosphorylation acts as a molecular 
switch that ultimately promotes transformation and overall tumorigenicity elicited by this 
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increase in MYC activity. This oncogenic activation of PERK could reflect a broader 
reliance of the transformed state on the UPR than that imposed in response to non-cell 
autonomous stress such as hypoxia and nutrient deprivation.227 
Carroll et. al. found that MYC deregulation increased MondoA (a MYC-related 
transcription factor that has been demonstrated to inhibit glucose uptake and aerobic 
glycolysis) expression in hepatocarcinoma, colon carcinoma, and neuroblastoma. This 
deregulation led to increases in lipogenesis to support cellular viability and increase the 
biomass of cancerous cells.228 Conversely, Qing et. al. found that MYC transformed cells 
underwent apoptosis in a human neuroblastoma model under glutamine starvation through 
ATF4 activation. This then led to the transcriptional activation of pro-apoptotic factors.229 
These studies demonstrate how MYC dependency acts as a double-edged sword and the 
characterization of MYC and ER stress responses will likely needed to be carried out in a 
tumor dependent context to elucidate its clinically relevant roles. 
 
4. Therapeutic Targeting of the ER Stress Response Pathways 
Due to demands made on cells by the malignant process, induction of ER stress 
response pathways is likely to be an important contributor to tumor survival and growth. 
There is a division of strategies for targeting the ER stress response. The first approach is 
to increase the amount of misfolded proteins in the ER to overload the protein folding 
requirements, inducing more severe ER stress and cell death. The second approach is to 
inhibit the adaptive and prosurvival response of the UPR, leading to an increase in 
sensitivity to anticancer therapy. The ideal scenario would be a dual approach that 
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overloaded the folding capacity of the ER while simultaneously inhibiting the UPR so cells 
are under severe stress and unable to resolve it causing cell death.230  
An activated ER stress response could be a key driver in the development of 
resistance to chemotherapeutic agents. Thus, a major challenge of cancer therapy will be 
finding a therapeutic window where it is possible to selectively kill cancer cells without 
harming normal cells. Even during treatment with ER stress inducing anticancer agents, 
tumor cells might paradoxically be more resistant to these agents than normal cells. 
Fortunately, the activation of the UPR is relatively small in a subset of secretory normal 
cell types in comparison to its activation in tumor cells.  
Several anticancer strategies have been recently studied in relation to ER stress, 
which may directly or indirectly affect tumors. The effects of drugs on non-tumorigenic 
cells remain under investigation.  In malignant myeloma cells, the IRE1α inhibitor Irestatin 
mediates the inhibition of XBP1’s transcription activity, inhibiting the UPR and disturbing 
malignant growth.209 GSK2656157 inhibits PERK and eIF2α phosphorylation, disrupting 
ATF4 translation and CHOP mRNA expression. Overall, this inhibition of PERK signaling 
reduces cancer cell growth by impairing amino acid metabolism and angiogenesis in 
multiple myeloma and pancreatic cancer.231  
Delta(9)-tetrahydrocannabinol also increase the phosphorylation of  eIF2α, 
activating the ER stress response in glioma cells.232 In some human leukemia and ovarian 
cancer cell lines, the induction of BiP, CHOP, phospho-eIF2α, and XBP1 splicing by 
Resveratrol233 and PDI inhibition by PABA/NO causes cell death.234 With regards to 
chaperone proteins, Honokiol binds to the unfolded ATPase domain of BiP with the 
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consequent induction of ER stress in melanoma and glioblastoma.235 Moreover, the 
inhibition of HSP90 activity by either Retaspimycin236 or SNX-2112 has shown great 
promise in gastrointestinal stromal tumors, non-small cell lung cancer, and prostate 
cancer.237 
Inhibition of protein clearance pathways that are involved in the degradation of 
misfolded proteins generated at the ER are predicted to trigger a strong stress response and 
decrease the survival of the UPR dependent tumors. There are small molecule inhibitors of 
ERAD, some of which directly target the proteasome like Bortezomib238, 239 and 
MG132.240, 241, 242 These inhibitors induce ER stress by inhibiting the proteasome, thus 
activating ERAD with an increase in misfolded proteins. Other modulators block ER client 
dislocation or ERAD components such as p97. Such ATPase inhibitors are alkylsulphanyl 
-1,-2,-4 triazoles, DBeQ, CB-5083, and eeyarestatin. A block in ERAD, following the 
inhibition of p97 function is likely to lead to irresolvable proteotoxic stress leading to a 
potential targetable vulnerability in cancer cells.243 
 
5. Conclusions 
 Tumor cells are highly proliferative and require effective, high energy producing 
systems to support their characteristic high rates of proliferation compared with 
nontumorigenic cells. Tumor cells can thrive under oncogenic stress of the tumor 
microenvironment and utilize the UPR and ERAD as an adaptation strategy for survival. 
As most normal cells are not subjected to stress, with the exception of hematopoietic, gut 
and hair follicle stem cells that experience stress due to their proliferative nature, the ER 
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stress response pathways remain inactive again differentiating between tumor and 
nontumorigenic cells. This differentiation might offer an advantage for targeting the ER 
stress response pathways to achieve specificity in cancer therapy. If tumor cells are exposed 
to another form of ER stress, such as a cytotoxic intervention, the intensity of the stress 
might be a threshold promoting the induction cell specific death in tumor cells with less 
effect on nontumorigenic cells. 
 
C. Ubiquitin Fusion Degradation 1 
1. Introduction 
Ubiquitin fusion degradation 1 (UFD1) was originally found in screens of 
saccharomyces cerevisiae mutants that showed UFD1 binds with ubiquitin, an interaction 
that is essential for the transfer of substrates to the proteasome. This regulated protein 
degradation has shown to be involved in a number of biologically important processes like 
development, cell cycle progression, and tumorigenesis. The precise mechanisms that are 
responsible for the recognition of ubiquitinated proteins and the processes leading  to 
proteasome mediated degradation are currently ill-defined.244, 245 
 
2. The Structure of Ubiquitin Fusion Degradation 1 
Sequence analysis of UFD1 has aided in revealing its structural features. Moreover, 
by using yeast to study deletion mutants the N-terminal portion of UFD1 was found to 
contain ubiquitin binding sites, while the C-terminal region was found to be important for 
the binding of two UFD1 cofactors,  nuclear protein localization 4 (NPL4) and p97.246, 247 
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The N domain of UFD1 is composed of two readily identifiable subdomains designated as 
Nn and Nc. Nn adapts the double-psi beta barrel fold while the Nc subdomain has a mixed 
α/β roll structure.248 The Nn subdomain of UFD1 contains ubiquitin binding sites  in the 
UT3 portion (residues 1-211).249 There are two distinct ubiquitin binding sites for either 
mono- or polyubiquitin, a feature that can be attributed to the utilization of separate binding 
sites with different affinities and representative of distinct cellular signaling pathways. It 
is further reasoned that due to the lack of one positive charge around the K48 residue of 
ubiquitin, as a result of the formation of isopeptide bonds on polyubiquitin, the electrostatic 
differences could serve to explain the necessity of different binding of ubiquitin. Another 
proposal is that the separate binding domains are to accommodate larger domains (145 
residues) versus smaller domains (>50 residues).249  
In particular UFD1 shows a higher affinity toward poly- than monoubiquitin. The 
interaction between UFD1 and ubiquitin involves hydrophobic contacts similar to those in 
well characterized ubiquitin binding proteins. 249  In regards to the binding of ubiquitin, 
residues affected by UFD1 binding are either in or very close to the hydrophobic patch on 
the ubiquitin surface involving L8, I44, and V70. The polyubiquitin binding residues are 
located in the regions formed by the psi-2 loop, helix2, sheet3, sheet6, and the alpah2-beta4 
loop. The monoubiquitin residues bind in sheet2, psi-1 loop, and helix3. The 
monoubiquitin binding sites on the UFD1 side are also mostly hydrophobic involving: C27, 
Y28, I30, A31, M32, I37, K39, W99, M100, M101, and G109.  Monoubiquitin signaling 
has been implicated in receptor endocytosis or DNA repair, suggesting that UFD1 might 
be involved in these processes through monoubiquitin binding.249  
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The C-terminal, UT6 fragment (residues 215-307) encompasses the binding sites 
for both NPL4 and p97.249 An 11 residue long SHP box on UFD1 binds at the far most side 
of the Nc lobe of the p97 N domain. This binding occurs primarily through hydrophobic 
interactions such that F225, F228, N233, and L235 of the SHP box contact hydrophobic 
residues on the surface of the p97 Nc lobe.250,251 Within the SHP domain, there are two 
glycine residues that produce a sharp kink. This geometry enables the bending of the UFD1 
SHP box upon binding to p97.252, 253 NPL4 binds to UFD1 by two regions, a conserved 
stretch of amino acids from residue 113 to 225 within its zinc finger domain and by NPL4 
homology between residues 263-344. In opposition, UFD1 binds NPL4 through a stretch 
of 18 amino acids within its C terminal, UT6 domain.252 
It’s known that p97 and UFD1 have an overall similar structure of their N domain. 
Moreover, it has been suggested that both p97 and UFD1 bind polyubiquitin in a synergistic 
manner.  The synergistic binding between p97 and UFD1 occurs first through the binding 
of polyubiquitin. 254, 255 Through its C domain, UFD1 binds the N domain of p97 (while 
subsequently interacting with NPL4 through its C domain).247 This binding puts the double-
psi barrels of UFD1 and p97 in close proximity providing avidity for synergistic binding 
to polyubiquitin. Additional synergy might be gained due to the hexameric nature of p97. 
While there is confirmation of a 1:1 interaction stoichiometry, the six N domains of p97 in 
one complex can in theory bind six UFD1-NPL4 molecules providing an opportunity for 
large capacity polyubiquitin association to occur. Polyubiquitin chains may bend around 
the hexamer for continued binding with even higher avidity.249  
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3. The Known UFD1 Interaction Partners 
a. Cytosolic Interaction Partners 
Similar to the discovery of UFD1, NPL4 was identified in a mutant screen where 
the NPL4 mutants were found to be strongly deficient in ERAD at a temperature permissive 
for nuclear import and export. These findings suggest that its role in ERAD is its primary 
function and not a secondary result of deficient nuclear transport.256 Overall, the 
degradation defects in mutants was characterized as quite general as the mutants were 
capable of crossing several ubiquitin ligase boundaries in the stabilization of both 
misfolded and deregulated proteins. The general proteasome function of these mutants was 
not deficient, again isolating the role of NPL4 to a post-ubiquitination but pre-proteasome 
degradation step in ERAD. The loss of NPL4 was able to induce the UPR, further 
ascertaining that NPL4 displays ‘ER centric’ behavior in that it is broadly required for ER 
protein degradation, but does not appear to affect cytosolic protein degradation.257 
The valosin-containing protein, p97, is a hexameric ATPase of the type II AAA 
family.258 p97 acts broadly in the recognition and presentation of ubiquitinated proteins to 
the 26S proteasome. Interestingly, p97 can selectively recognize ubiquitinated proteins, 
and while it can bind mono-, di- or tri- ubiquitin moieties in vitro it preferentially binds 
tetra-ubiquitinated chains. Each protomer comprises an N-terminal domain, two ATPase 
domains in tandem (D1 and D2) which form a doubly packed, hexameric ring with a short 
C-terminal region. These two ATPase domains are functionally coupled such that the 
activity of D1 depends on both ATP binding and hydrolysis by the D2 domain, suggesting 
that the D1 domain likely hydrolyzes ATP when D2 is in its ADP-bound form. The 
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molecular activity of p97 itself is rather simple, employing the hydrolysis of ATP to 
generate large conformational changes.246 
The functional diversity of p97 is realized through interactions with many different 
adaptor proteins. Such cellular processes include: ERAD, post-mitotic golgi reassembly, 
cell cycle regulation, apoptosis, DNA damage response, mitochondria quality control, and 
autophagy.259 Interestingly p97 is among one of the most abundant cellular proteins 
representing approximately 1% of total cellular protein.260 The most well-known co-factors 
of p97 are UBX domain-containing protein 2C (p47) and the UFD1- NPL4 complex. In a 
mutually exclusive manner, p47 and p97 appear to play a role in the homotypic fusion of 
ER and golgi members.261  
There is also a known, direct interaction between UFD1 and gp78. The co-factor 
gp78 is a membrane-anchored ubiquitin ligase that promotes the degradation of misfolded 
ER proteins and sterol-regulated degradation of HMG-CoA reductase to valonate in a rate 
limiting step in the synthesis of cholesterol. The monoubiquitin binding site in UFD1 is 
required for the enhancement of gp78 activity, while the polyubiquitin site of UFD1 
remains available for the post-ubiquitination step in ERAD.262   
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Figure 1.4. Identification of the significant cytosolic functional partners of UFD1 and their 
corresponding residues of interaction. 
 
 
b. Nuclear Interaction Partners 
 In the nucleus, UFD1 acts as a scaffold for s-phase kinase associated protein 2 
(SKP2) and the deubiquitinating enzyme USP13 (ubiquitin specific peptidase 13). Through 
UFD1 truncation mutants, the interaction between UFD1 and USP13 in in vivo binding 
was localized to the amino acid residues 261-280 of UFD1, distinct from the binding sites 
of p97.263 
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4. Implicated Pathways with UFD1 Function 
a. Cytosolic Pathways 
The ubiquitin proteasome pathway has a defined beginning and end. Target proteins 
are first recognized by upstream components and tagged with polyubiquitin chains. In the 
ubiquitin proteasome pathway, 8 kDa ubiquitins (in multiple copies) are covalently 
attached to a target protein creating the polyubiquitin chain that serves as a signal for 
translocation to the proteasome. These polyubiquitinated substrates are then taken to the 
26S proteasome to be degraded.264  
Functionally, UFD1 is best known for its association with NPL4. This complex 
binds p97 in a mutually exclusive manner. In complex, they are a founding member of the 
growing family of adaptor proteins that direct AAA-ATPase (ATPases are associated with 
a diverse set of cellular activities) p97 to specific cellular functions.265 Experiments have 
placed the UFD1-NPL4-p97 complex in the path between ubiquitination and degradation 
in two well studied processes: ERAD and ubiquitin-mediated processing.266, 267 Together, 
UFD1 and NPL4 confer AAA-ATPase p97 specific activity in ERAD, which is part of the 
UPR and is critical for restoring homeostasis in the ER when it’s endogenous functions 
have been perturbed by such incidences as accumulated misfolded and/or unfolded protein.  
Each member of this complex is required for ERAD and the loss of each one results in a 
broad defect in the process.268  
The model UFD1-NPL4 heterodimer interaction proposes that the complex forms 
a regulatory gate at the exit from the retrotranslocon rather than actively promoting 
retrotranslocation like p97. The heterodimer exists either alone or bound to the ubiquitous, 
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highly conserved ATPase p97. While the degradation of typical ERAD substrates depends 
on p97, their degradation doesn’t require UFD1or NPL4.269 The functions of UFD1 and 
NPL4 can be separated, indicating the independent roles of each component.270 While 
purified UFD1 binds p97, purified NPL4 doesn’t bind p97 in the absence of UFD1; 
however, both components of UFD1-NPL4 dimer cooperatively bind p97. In fact NPL4 
enhances UFD1 binding to p97 when forming the heterodimer.261, 265, 268 
Substrate binding occurs when the first ATPase domain of p97 is in its nucleotide-
bound state, an interaction that also requires an association of p97 with the ER membrane 
through its N domain. One elongated, bilobed UFD1-NPL4 heterodimer, in conjunction 
with a bound polyubiquitinated polypeptide, sits on the peripheral region of the p97 
hexamer ring as illustrated through electron microscopy analyses. Alternatively, the 
ATPase itself can interact with unmodified polypeptide substrates as they emerge from the 
ER membrane. The binding to the polyubiquitin chain may activate the ATPase p97 to pull 
the polypeptide substrate that is also bound by the UFD1-NPL4 heterodimer, out of the 
membrane. The polypeptide substrate is transported through the central pore in the double-
barrel p97 structure in the direction of the D1 ring towards the D2 ring. While the exact 
mechanism of protein dislocation from the ER remains unknown, it appears the two 
ATPase domains (D1 and D2) of p97 alternate in ATP hydrolysis, providing the 
mechanical force for the movement of polypeptides from the ER membrane into the 
cytosol.246  
A growing number of studies have suggested that the UFD1-NPL4-p97 complex is 
involved in the proteasomal degradation of various proteins not only from the ER 
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membrane but from other cellular locations as well such as the nucleus, mitochondrial 
membrane, ribosomal, and even cytosolic multi-protein assemblies.271,272 Thus, p97 
inhibitors are under development as an anti-cancer therapy agents which target  proteotoxic 
stress of cancer cells in a similar manner to proteasome inhibitor.273  
RNAi-mediated depletion of UFD1 in mammalian cells has yielded conflicting 
results.263 While some studies reported impaired ERAD in UFD1-depleted cells, others 
showed an accelerated rate of degradation of classical ERAD substrates such as cholera 
toxin274 and T cell receptors.275 Although some of these contradictory results can be 
attributed to the use of distinct cellular systems, they point to the great complexity in the 
regulation and function of UFD1 that impinges on the ER stress response, a motivation for 
our studies to provide clarity to the functional and mechanistic implications of UFD1 loss 
in tumor models. 
In mammalian cells, UFD1 also directly enhances the activity of gp78, a ubiquitin 
ligase that is involved in ERAD, independent of NPL4 and p97. UFD1 functions to enhance 
the E3 activity of gp78, accelerating the ubiquitination and degradation of valonate, 
eventually promoting receptor-mediated uptake of  low-density lipoprotein.262 The stability 
of HMG-CoA reductase is tightly regulated in cells as the protein is degraded through the 
ERAD pathway in the presence of high levels of sterol.276, 277 The monoubiquitin binding 
site in UFD1 is required for the enhancement of gp78 activity leaving the polyubiquitin 
binding site in UFD1 as the critical site for post-ubiquitination step in ERAD.262  
b. Nuclear Pathways 
UFD1 has additional roles beyond ERAD. UFD1 has been implicated in nuclear 
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envelope assembly and in the disassembly of the mitotic spindle. In xenopus laevis egg 
extracts,278 the UFD1-NPL4-p97 complex promoted chromatin decondensation and 
regulated spindle disassembly; however, there is still a lack of mechanistic information 
regarding these processes. 279 
 Another known function of UFD1 in a nuclear function, is its role as a negative 
regulator of SKP2.  In the nucleus, UFD1 acts as a scaffold for SKP2 and the 
deubiquitinating enzyme USP13, antagonizing the degradation of SKP2. In the instances 
of prolonged ER stress nuclear UFD1 levels are downregulated, triggering SKP2 
destabilization and accumulation of p27 leading to a delayed cell cycle progression in G1. 
This demonstrates that UFD1 facilitates the degradation of misfolded proteins in G1-
arrested cells, insinuating that there is a link between UFD1 and cell-cycle controls that 
would serve to optimize ERAD.263  
Importantly, the changes in expression of UFD1 and SKP2 are largely in the nuclear 
fraction, implying that the pool of UFD1 that contributes to cell-cycle control is distinct 
from that involved in the retrotranslocation of misfolded proteins in the cytosol. Thus, a 
proposed model highlights that the functions of UFD1 are regulated temporally and 
spatially under conditions that activate the UPR. In an immediate phase of activation, 
UFD1 in cooperation with p97 and NPL4 in the cytosol contribute to the retrotranslocation 
of misfolded proteins from the ER during ERAD. In a delayed response, the 
downregulation of nuclear UFD1 mediates SKP2 and p27 expression leading to G1 cell-
cycle delays permitting the increased clearance of misfolded proteins, likely through 
ERAD as well. 263 
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5. Cancer Associated Expression of Ubiquitin Fusion Degradation 1 
Metastatic cancers usually remain incurable with chemotherapy because of 
multidrug resistance. It is postulated that disturbances in the normal function of the UFD1-
NPL4-p97 complex lead to an accumulation of unfolded protein and can eventually trigger 
ER stress and cell death if the ER dysfunction is severe or prolonged. High expression 
levels of UFD1 in SWII6/HCPT colon cancer cell lines indicate that the UFD1-NPL4-p97 
complex might play an important role in resistance to the cytotoxic effect of 
hydroxycamptothecin.280  
 
6. Conclusions 
UFD1 mediates ubiquitin-mediated degradation through an association of NPL4 
and p97. The UFD1-NPL4-p97 functions in the recognition of several polyubiquitinated 
proteins and facilitates the presentation of substrates to the proteasome for specific 
processing or processive degradation. However, what happens in vivo, between the actual 
ubiquitination of a protein and the processing by the proteasome remains poorly 
understood. Our studies aim to understand the functional and molecular role of UFD1 in 
this process. Inquiries into differential expression levels of UFD1 in cancer cells have been 
fruitful in the cases of leukemia, colon, and triple-negative breast cancer and may provide 
initial platforms for the elucidation of the tumorigenic role of UFD1 that may be first 
explored in the tumor context then translated to other relevant tumor systems. The 
elucidation of the role of UFD1 in driving tumorigenesis, its mechanisms of interactions 
with its functional partners, coupled with structural understanding could encourage the 
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development of more effective inhibitors that target the ERAD stress pathway of cancer 
cells, which should have less adverse effects compared to conventional cytotoxic 
therapeutics. 
 
D. Dissertation Research Specific Aims 
1. Aim 1: Define the functional importance of UFD1 in MYC-driven T-ALL 
aggressiveness. 
2. Aim 2: Identify the molecular mechanisms by which UFD1 contributes to MYC-
driven T-ALL progression. 
3. Aim 3: Evaluate the potential of targeting UFD1-mediated pathways as a novel
 therapeutic approach. 
 
E. Dissertation Research Hypothesis  
Enhanced expression of UFD1 is critical for T-ALL pathogenesis by supporting T-ALL 
survival and proliferation, thus representing a novel therapeutic target. 
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CHAPTER TWO: UFD1 Contributes to MYC-Mediated Leukemia Aggressiveness 
Through Suppression of the Proapoptotic Unfolded Protein Response 	
A. Abstract 
Despite the pivotal role of MYC in tumorigenesis, the mechanisms by which it 
promotes cancer aggressiveness remain incompletely understood.  Here we show that 
MYC transcriptionally regulates the UFD1 gene in T-ALL.  Allelic loss of ufd1 in 
zebrafish induces tumor-cell apoptosis and impairs MYC-driven T-ALL progression but 
does not affect general health.  As the E2 component of an ERAD complex, UFD1 
facilitates the elimination of misfolded/unfolded proteins from the ER.  We found that 
UFD1 inactivation in human T-ALL cells impairs ERAD, exacerbates ER stress, and 
induces apoptosis.  Moreover, we show that UFD1 inactivation promotes the proapoptotic 
UPR mediated by PERK.  This effect is demonstrated by an upregulation of PERK and its 
downstream effector CHOP, as well as a downregulation of BCL2 and BCLxL.  Indeed, 
CHOP inactivation or BCL2 overexpression is sufficient to rescue tumor-cell apoptosis 
induced by UFD1 knockdown.  Together, our studies identify UFD1 as a critical regulator 
of the ER stress response and a novel contributor to MYC-mediated leukemia 
aggressiveness, with implications for targeted therapy in T-ALL and likely other MYC-
driven cancers. 
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B. Introduction 
Enhanced MYC activity contributes to malignant transformation, maintenance, and 
progression in over half of all human cancers, including leukemias, lymphomas, and 
carcinomas.55 T-ALL is an aggressive hematologic malignancy of developing thymocytes 
that afflicts both children and adults.281 In over 60% of T-ALL cases, MYC is 
overexpressed downstream of activated NOTCH1 mutations and plays a pivotal role in 
disease induction and aggressiveness.29, 37, 38, 49, 282 Despite a range of treatment 
improvements, 15% to 20% of pediatric and 50% of adult patients with T-ALL succumb 
to disease.281 Moreover, current multi-agent protocols often cause serious systemic 
toxicities, underscoring the need for better therapy.283 Improved understanding of the 
molecular mechanisms that underlie MYC-mediated leukemia aggressiveness may provide 
strategies for development of effective targeted treatments.     
It has been demonstrated that enhanced MYC activity leads to cellular changes 
associated with a global increase in gene transcription and protein synthesis.284-285 One 
consequence of this effect is an increase in misfolded/unfolded polypeptides in the ER, 
referred to as ER stress.230 In order to restore protein homeostasis in the ER, a number of 
stress response pathways are activated, including the UPR and ERAD pathways.13  The 
UPR is a well-conserved pathway among vertebrate species that inhibits general protein 
translation and upregulates specific ER chaperones to alleviate ER stress.  ERAD functions 
downstream of the UPR to facilitate the degradation of misfolded/unfolded proteins and 
thus helps to restore ER protein homeostasis.286 Although optimal cell function and 
survival depend on the coordinated functions of both UPR and ERAD,198 it remains unclear 
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how these pathways cooperate to promote tumor induction and progression.   
In cells with elevated ER stress, at least three types of ER stress transducers can be 
activated through the release of inhibitory binding BiP: PERK, IRE1, and ATF6. 115, 116 
Each transducer communicates ER stress to the cytosol and the nucleus to alter gene 
transcription, protein synthesis, and protein degradation.115, 116 Although the UPR is often 
cytoprotective, it can become cytotoxic when there is prolonged and unresolved ER stress, 
thus serving as a central regulator of cell fate.230 Identification of genes controlling this 
switch could deepen our understanding of the regulation of the ER stress response 
pathways and reveal new strategies for cancer treatment.  
 Here we identify the UFD1 protein as a novel mediator of MYC-driven leukemia 
aggressiveness and a suppressor of the cytotoxic UPR.  Our genomic and biochemical 
analyses of human patient samples pinpoint UFD1 as a MYC-activated protein that is 
significantly upregulated in T-ALL.  UFD1 functions in a major ERAD complex 
downstream of the UPR to retrotranslocate unfolded/misfolded proteins from the ER lumen 
to the cytosol for proteasome-mediated degradation.287 We demonstrate that UFD1 
inactivation impairs ERAD, exacerbates ER stress, and activates the PERK-mediated 
proapoptotic UPR to induce tumor-cell apoptosis.  Disruption of UFD1 function suppresses 
MYC-driven leukemia progression in vivo and kills human MYC-dependent T-ALL cells 
in vitro.  Our studies thus identify UFD1 as a key mediator of MYC-driven T-ALL 
progression and suggest that a targeted therapy strategy based on these findings could 
improve the outlook for patients with MYC-associated, high-risk T-ALL and perhaps those 
with other MYC-driven cancers.  
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C. Materials and Methods 
1. Zebrafish Husbandry, Tumor Surveillance, and Genotyping 
Zebrafish line maintenance and husbandry were performed as previously described 
in the aquatics facility at the Dana-Farber Cancer Institute under a subcontract and at the 
Boston University School of Medicine,288 according to standards set by the National 
Institutes of Health (NIH) and approved protocols of the Institutional Animal Care and Use 
Committee.  Both male and female AB fish younger than 2-year-old were included in the 
studies.  All transgenic and mutant fish were genotyped by gene-specific PCR using 
primers (Table 2.1) and DNA isolated from either the whole embryo or the tail fin of the 
individual adult fish as previously described.289 Surveillance for tumor onset and 
progression were conducted as previously described using published criteria.290 Tumor 
burden and disease stage were documented by imaging on both brightfield and 
EGFP/DsRED2 channels using a fluorescent microscope (MVX10; Olympus, Center 
Valley, PA, USA).   The images were quantified with Image J software and processed with 
Adobe Photoshop (Adobe Systems Incorporated, San Jose, CA, USA). 
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Primer Name Sequence 
rag2:EGFP-mMyc-F 5’-ACAGCGTCTGCTCCACCTCC-3’ 
rag2:EGFP-mMyc-R 5’- TGGCCTCGGGATGGAGATGA-3’ 
hsp70:cre-F 5’-TGGACATGTTCAGGGATCGC-3’ 
hsp70:cre-R 5’-GCCTGTTTTGCACGTTCACC-3’ 
rag2-promoter-F 5’- ATGCTAATTTGAAGCACTAGCA- 3’ 
dsRED2+333 5’- CCCACTTGAAGCCCTCGG- 3’ 
EGFP-130R 5’-GTGCAGATGAACTTCAGGGT- 3’ 
ufd1-wild-type-F 5’-GCACTTCCCACTGAAAGGAA-3’ 
ufd1-wild-type-R 5’-TTTGGAATAAACTTCCTCACATTTC-3’ 
ufd1-mutant-F 5’-CTGTTCCATCTGTTCCTGAC-3’ 
ufd1-mutant-R 5’-TTTGGAATAAACTTCCTCACATTTC- 3’  
rag1-F 5’ –AAATGGAAGGCCTGGAAGCATCGG- 3’ 
rag1-R 5’-GTGCAGATGAACTTCAGGGT- 3’ 
Table 2.1. Summary of Primers used for Genotyping.  
 
 
2.Gene Expression Analysis 
  For gene expression analysis of patient samples, previously published gene 
expression datasets (GSE33470 and GSE42328) were obtained from the NCBI Gene 
Expression Omnibus, and reanalyzed in this study.291  Both of the studies were carried out 
on the Illumina HumanHT-12 V4.0 Expression BeadChip.  To compare the differential 
gene expression profiles between normal T cells and T-ALL patient samples, we merged 
data from the two series of records and applied quantile normalization to the raw data to 
remove sources of variation between different experiments.  The GSEA system from the 
Broad Institute was used to analyze for the enrichment of the ER stress signature in T cells 
and T-ALL patient samples.  We calculated an enrichment score that reflects the degree to 
which the gene set is overrepresented at the extremes (top or bottom) of the entire ranked 
list.  The result is significant at False Discovery Rate (FDR) < 25% and at nominal P-
values ≤ 5%.  
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3. Clinical Samples of Leukemic Cells 
Primary human T-ALL samples were collected from the Dana-Farber Cancer 
Institute or the University of Massachusetts Memorial Hospital, with informed consent and 
with the approval of the Institutional Review Board.  Leukemic blasts were isolated from 
peripheral blood or bone marrow and subsequently expanded in female Nod-Scid-Gamma 
(NSG) mice that were <10 weeks old as previously described.282 Primary human T-ALL 
cells used in this research were isolated from the spleen and bone marrow of NSG mice.  
The Institutional Animal Care and Use Committee at the University of Massachusetts 
Medical School approved all animal procedures used in this study.  All samples were 
analyzed without linked identifiers. 
   
4. Protein Extraction and Western Blotting 
Zebrafish thymocytes, lymphoblasts, or human T-ALL cells were lysed in RIPA 
buffer (1% NP-40, 0.1% SDS, 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% sodium 
deoxycholate, and 1 mM EDTA) supplemented with Halt proteinase and phosphatase 
inhibitor cocktail (Thermo Scientific, Cambridge, MA, USA).  Primary antibodies included 
anti-MYC (Santa Cruz, Dallas, TX, USA or Cell Signaling, Danvers, MA, USA or Thermo 
Fisher, Waltham, MA, USA), anti-UFD1 (Fitzgerald, Acton, MA, USA or Proteintech, 
Rosemont, IL, USA), anti-CD3δ (Gene Tex, Irvine, CA, USA), anti-BCL-2 (Santa Cruz, 
Dallas, TX, USA), anti-ACTIN (Santa Cruz, Dallas, TX, USA), anti-ATF6 (Abcam, 
Cambridge, MA, USA), and anti-phospho-IRE1α Serine 724 (Novus Biologicals, Littleton, 
CO, USA), as well as the following: anti-PERK, anti-phospho-PERK, anti-IRE1α, anti-
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CHOP, anti-BiP, anti-VCP/P97, anti-NPL4, anti-cleaved PARP, and anti-BCLxL, all of 
which were from Cell Signaling (Danvers, MA, USA).  Secondary antibodies included 
horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibodies (Pierce, 
Cambridge, MA, USA).  Autoradiographs were acquired with a G:BOX Chemi XT4 
(Syngene, Frederick, MD, USA) and a CCD camera, and subjected to quantification 
analysis with ImageJ software. 
 
5. Quantitative Real Time PCR (qRT-PCR) 
Total RNA was isolated using an RNeasy kit (Qiagen, Valencia, CA, USA), and 
cDNA was synthesized using a reverse transcriptase kit (Qiagen, Valencia, CA, USA).  
About 100 ng of cDNA was used for each qRT-PCR reaction performed with SYBR green 
PCR master mix (Qiagen, Valencia, CA, USA) and a Step-One PCR instrument (Applied 
Biosystems, Foster City, CA, USA) according to the manufacturer’s manual.  Primer 
information is included in Table 2.2. 
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Primer Name Sequence 
shUFD1 #1    5’ -CTGGCAATAGACTGGATGGAA- 3’ 
shUFD1 #2 5’ -TGGGCTACAAAGAACCCGAAA- 3’ 
shUFD1 #3 5’ -GCAATTCTGCATCCCTAATTC- 3’ 
shUFD1 #4 5’ –GCAGCAGGACTTTGTAGTTGT- 3’ 
shTAL1 5’ -GCTCAGCAAGAATGAGATCCTC- 3’ 
shCHOP 5’ -GCACCAAGCATGAACAATTGG- 3’ 
z-b-actin-RT-F 5’-TACAATGAGCTCCGTGTTGC-3’ 
z-b-actin-RT-R 5’- ACATACATGGCAGGGGTGTT -3’ 
h-UFD1-CHIP-F1 5’- CCAATGGGGCAGCATTTACG -3’ 
h-UFD1-CHIP-R1 5’- ACCCACAATGCACTACCCAG -3’ 
h-UFD1-CHIP-F2 5’- GCTGGGCGGACATCTTTACT -3’ 
h-UFD1-CHIP-R2 5’- CGTAAATGCTGCCCCATTGG -3’ 
h-b-ACTIN-CHIP-F1 5’- CCCAATCCTCTGTGGCACAT -3’ 
h-b-ACTIN-CHIP-R1 5’- CCGTCCGTTGTATGTCTGCT -3’ 
h-b-ACTIN-CHIP-F2 5’- CCCCAACACCACACTCTACC -3’ 
h-b-ACTIN-CHIP-R2 5’- TTGCCGACTTCAGAGCAACT -3’ 
Table 2.2. Summary of primers used for qRT-PCR and CHIP-PCR.  
 
6. Lentiviral Transduction and Cell Growth Evaluation 
T-ALL cell lines were cultured in RPMI 1640 (Corning Inc., Corning, NY, USA) 
supplemented with 10% fetal bovine serum (FBS, Life Technologies, Waltham, MA, 
USA).  The published and unpublished shRNA hairpin sequences for UFD1, TAL1, and 
CHOP that had been cloned into PLKO.1-puro vector are included in Table 2.2.5  The three 
shMYC/PLKO.1 constructs (TRCN000010390, TRCN000039638 and TRCN000039640) 
were purchased commercially (Dharmacon, Lefayetta, CO, USA).  Lentiviral production 
was conducted as previously described.37 After lentiviral transduction, cells were 
maintained in media containing puromycin (1.0 µg/mL).  The knockdown effect for each 
gene was verified by Western blot analysis and cell growth was determined via 
hemocytometer counting.  Cells were plated in triplicate and counted every other day 
starting at day 4 postinfection and ending at day 12 postinfection. 
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7. Firefly luciferase assay, ChIP-PCR and ChIP-Seq analysis 
Human T-ALL cells were transfected with LightSwitch promoter constructs for 
UFD1 or b-ACTIN (ACTB) (Switchgear Genomics, Carlsbad, CA, USA) at day 3 
postinfection.  Luciferase assays were performed at 30 hours posttransfection using a 
commercial luciferase kit (Switchgear Genomics, Carlsbad, CA, USA).   
Human T-ALL cells were cross-linked, sonicated, and subsequently subjected to 
ChIP using a commercial ChIP kit (Epigentek Group Inc., Farmingdale, NY, USA), 
together with an anti-MYC or anti-polymerase II or anti-IgG antibody.  The input and 
resultant ChIP DNA were subjected to PCR using two UFD1 and ACTB primers (Table 
2.2), spanning their respective promoters. 
 
 
8. Paraffin-embedded Sectioning and hematoxylin and eosin (H&E) Staining 
Fish were fixed with 4% paraformaldehyde, embedded in paraffin, and 
subsequently sectioned into 5-micron-thick slices with a Microtome (Leica Biosystems, 
Wetzlar, Germany).  The slides were dewaxed in fresh xylene, stepwise rehydrated with 
100, 95, 80 and 75% ethanol and water, and stained with hematoxylin.  Stained slides were 
then rinsed in distilled water and immersed briefly in 1% acid alcohol.  Finally, slides were 
counterstained with eosin solution for 10–30 seconds, followed by stepwise dehydration. 
 
9. Cytospin, May-Grunwald-Giemsa Staining, and Immunofluorescence Staining 
Cytospin slides were prepared using GFP+ thymocytes or T-ALL cells from 
zebrafish.  250,000 cells were spun at 350 rpm for 4 minutes.  Slides were air dried 
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overnight followed by methanol fixation for 15 minutes and then stained with May-
Grunwald-Giemsa solution at pH 7.  Images were captured using Nikon immersion oil 
technology (Nikon Instruments Inc., Melville, NY, USA) and Leica microscope imaging 
software (Leica Microsystems, Buffalo Grove, IL, USA).  For immunostaining, cytospin 
slides were fixed with 1% paraformaldehyde, washed in PBS, post-fixed in pre-cooled 
ethanol: acetic acid (2:1) at -20ºC, and incubated with anti-active caspase-3 (Thermo 
Scientific, Waltham, MA, USA) overnight at 4ºC.  Nuclei were counterstained with DAPI 
(Sigma, St. Louis, MO, USA).  Slides were mounted with vector shield mounting solution 
(Sigma, St. Louis, MO, USA) and imaged using a Nikon deconvolution wide-field 
epifluorescence system (Nikon, Minato, Tokyo, Japan) and processed using Fiji software.49 
 
10. Cell Cycle and Apoptosis Assays 
For cell cycle analysis, zebrafish thymocytes and tumor cells were stained with 
Vybrant® DyeCycle Ruby Stain (Invitrogen, Carlsbad, CA, USA) as previously 
described.29 Zebrafish tissues dissected from each individual fish or human T-ALL cells 
harvested from media were stained with Annexin V (BD Biosciences, San Jose, CA, USA) 
and PI (50 µg/mL; Sigma, St. Louis, MO, USA) for 20 minutes.  For cell cycle analysis of 
human T-ALL cells, cells were fixed in ethanol and incubated at -20°C overnight and 
stained in PI solution (PBS, 50 µg/ml PI, and 100 µg/ml RNase A) for 20 min at 4°C.  The 
LSRII flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) and FlowJo software 
(FlowJo, LLC) were used for data collection and analysis. 
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11. Tunicamycin Treatment and Thioflavin T Staining 
Human T-ALL cells were either treated with vehicle (ethanol) or tunicamycin (5 
µg/mL; Sigma, St. Louis, MO, USA), or transduced with shLuciferase, shUFD1 #1, or 
shUFD1 #2.  Subsequently, cells were fixed in 4% paraformaldehyde and permeabilized 
with 0.05% Triton-X.  After blocking with 5% BSA, cells were incubated with 5 µM 
Thioflavin T (Sigma, St. Louis, MO, USA).  Images were captured using a Nikon 
deconvolution wide-field epifluorescence microscope (Nikon, Minato, Tokyo, Japan) and 
processed by Adobe Photoshop (Adobe Systems Incorporated, San Jose, CA, USA).   
 
12. Statistical Analysis 
Kaplan-Meier analysis and the log-rank test were used to compare times to tumor 
onset and progression between Myc;Cre;ufd1+/+  and  Myc;Cre;ufd1+/-  fish.  Student’s 
t-test was used to analyze differences in gene expression, tumor burden, cell cycle, number 
of active caspase-3+ cells, protein levels, Annexin-V-stained cells, and cell viability 
between control and experimental group, or between any two groups of cells with different 
genotypes.  P-values ≤0.05 were considered statistically significant, and not adjusted for 
multiple comparisons. 
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D. Results 
 
1. Human T-ALL cells show elevated levels of ER stress and upregulate UFD1 in a 
MYC-dependent manner 
a. Human patient T-ALL samples show signs of ER stress  
 
 
Figure 2.1. Human patient T-ALL samples show signs of ER stress.  
 
(a) Gene set enrichment analysis of publicly available datasets revealed that a previously-defined ER stress 
signature is significantly enriched in T-ALL patient samples, compared with normal T cells (P=0.01; n=53 
and 21, respectively). (b) Heat map of a previously-defined ER stress signature revealed that a majority of 
ER stress response genes were upregulated in primary T-ALL patient samples,38 compared to normal T cells. 
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Figure 2.2. Human patient T-ALL samples upregulate ER stress response factors in the UPR and 
ERAD pathways.  
 
Gene expression heatmap for MYC, genes in three branches of the UPR pathway, and genes encoding the 
major ERAD complex (UFD1, NPL4, and P97) from the same datasets analyzed in (Fig. 2.1).   
 
 
Aberrant MYC activity promotes gene transcription and protein translation, leading 
to an accumulation of misfolded/unfolded polypeptides in the ER (i.e., ER stress).292, 285  
To determine the level of ER stress in human MYC-dependent T-ALL cells, we utilized 
publicly available databases to compare gene expression profiles between primary human 
T-ALL and normal T-cell samples (GSE33470 and GSE42328).291  Gene set enrichment 
analysis (GSEA) of these datasets revealed that human T-ALL cells are significantly 
enriched for a previously-defined ER stress signature (Fig. 2.1a-b),122 indicative of elevated 
ER stress in these tumor cells.   
To understand how T-ALL cells cope with ER stress, we analyzed the expression 
of genes involved in all three branches of the UPR,293 as well as components of the major 
ERAD complex (UFD1-NPL4-p97) in human T-ALL samples and normal T cells.287 
Strikingly, the transcript levels of all UPR/ERAD-related genes analyzed, except IRE1α, 
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were significantly elevated in human T-ALL samples compared to normal T cells (Fig. 
2.2).  
 
b. IRE1α and ATF6 are not upregulated in MYC-overexpressing T-ALL patient samples 
 
 
Figure 2.3. Human patient T-ALL samples upregulate UFD1 in a MYC-dependent manner.   
 
Western blot analysis (left panel) of MYC, ATF6, P-PERK (phospho-PERK), PERK, UFD1, NPL4, and P97 
in thymus (denoted as blue) and primary T-ALL patient samples with high (denoted as red) or low (denoted 
as purple) MYC expression.  Protein quantification (right panel) revealed that MYC-high T-ALL patient 
samples have higher expression levels of UFD1 but not NPL4 or P97, compared to MYC-low tumor samples 
(mean ± SD of UFD1 to ACTIN ratio: 0.39 ± 0.08 vs. 0.08 ± 0.002, P=0.028; NPL4 to ACTIN ratio: 0.12 ± 
0.02 vs. 0.06 ± 0.02, P=0.154; and P97 to ACTIN ratio: 0.21 ± 0.04 vs. 0.18 ± 0.06, P=0.63; n=6 for MYC-
high and 3 for MYC-low T-ALL patient samples).   
 
 
 
 
 
 
  
 
 
 
 
 
	71	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. IRE1α and CHOP are not upregulated in MYC-overexpressing T-ALL patient samples.   
 
Western blot analysis of IRE1α and CHOP in human primary thymus and T-ALL patient samples with high 
(red font) and low (blue font) MYC expression.  ACTIN served as a loading control. 
 
Next, we analyzed protein levels of the UPR components and the UFD1-NPL4-p97 
ERAD complex.  As expected, 227, 282 protein levels of MYC and phospho/total PERK, but 
not CHOP or IRE1a were increased in most primary T-ALL samples (Fig. 2.3 and Fig. 
2.4).   
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c. Human T-ALL patient samples upregulate UFD1 in a MYC-dependent manner 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. MYC and UFD1 but not other UPR and ERAD components are upregulated in human T-
ALL cell lines.   
 
 (a) Western blot analysis of MYC and components of the UPR and UFD1-mediated ERAD in three 
primary thymus samples and a panel of human T-ALL cell lines.  Note: LOUCY cell line (red) expresses N-
MYC.10  ACTIN serves as a loading control.  (b-c) Quantification of MYC (b) and UFD1 (c) protein levels 
revealed that both UFD1 and MYC protein levels were significantly elevated in human T-ALL cells, 
compared to normal thymus (mean ± SD of MYC to ACTIN ratio: 0.5871 ± 0.1165 vs. 0.0086 ± 0.0002, 
P=0.0138; ACTIN ratio: 0.9418 ± 0.1942 vs. 0.1845 ± 0.0349, P=0.0466; n=8 and 3 respectively). 
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Surprisingly, among the three UFD1-NPL4-p97 ERAD components, only UFD1 
was significantly upregulated in MYC-overexpressing T-ALL samples, compared to those 
with lower MYC expression (Fig. 2.3).  Finally, we performed Western blot analysis on a 
panel of human MYC-dependent T-ALL cell lines to detect protein levels of the above 
UPR and ERAD components.  Consistent with what we observed in MYC-overexpressing 
patient samples, MYC and UFD1 were significantly upregulated in human T-ALL cell 
lines, compared to control thymus (Fig. 2.5a-c).  Additionally, we observed upregulation 
of phospho/total PERK and ATF6 in some of human MYC-dependent T-ALL cell lines, 
indicative of ER stress.  Together, our studies demonstrate that human T-ALL cells are 
primed with ER stress and upregulate UFD1 in a MYC-dependent manner.   
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2. MYC transcriptionally regulates UFD1 in MYC-dependent T-ALL cells 
a. MYC inactivation in JURKAT human T-ALL cells decreases UFD1 expression 
 
Figure 2.6. MYC transcriptionally upregulates UFD1 in human leukemic cells.  
 
Western blot analysis of human BCL2-overexpressing JURKAT T-ALL cells revealed that P-PERK, PERK 
and CHOP decreased upon shMYC or shTAL1 knockdown; however, UFD1 protein levels decreased only 
upon shMYC knockdown.  ACTIN serves as the loading control.   
 
To determine if MYC regulates UFD1, we inactivated MYC by short hairpin RNA 
(shRNA) in human BCL-2-overexpressing and thus apoptosis-resistant JURKAT T-ALL 
cells.  Western blotting revealed that UFD1, but not p97 or NPL4, was downregulated in 
these cells upon MYC knockdown (Fig. 2.6).  MYC inactivation also suppressed PERK-
mediated UPR, as demonstrated by decreased expression of phospho/total PERK and its 
downstream effector C/EBP homologous protein (CHOP), while minimally affecting 
ATF6 and IRE1α (Fig. 2.6).  Similar to MYC knockdown, inactivation of TAL1, another 
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major T-ALL oncogene, also downregulated phospho/total PERK and CHOP, but did not 
decrease UFD1 protein levels, suggesting that UFD1 is specifically regulated by MYC but 
not TAL1 or PERK (Fig. 2.6).   
 
b. MYC inactivation in JURKAT human T-ALL cells reduces UFD1 promoter region and 
specifically binds to the promoter region of UFD1 
 
Figure 2.7. MYC specifically binds to the promoter region of UFD1. 
 
(a) Firefly luciferase assays show that MYC inactivation significantly reduced UFD1 promoter activity.  (b) 
CHIP-PCR demonstrates that MYC binds to the promoter region of UFD1 but not b-ACTIN (ACTB) gene.  
Schematic drawing on the top illustrates the primer location within the UFD1 or ACTB promoter. 
 
 
To understand if MYC regulates UFD1 transcriptionally, we performed firefly 
luciferase assays to measure UFD1 promoter activity in BCL-2-overexpressing JURKAT 
T-ALL cells.  MYC inactivation significantly reduced UFD1 promoter activity, leading 
to a reduced expression of the luciferase reporter gene (Fig. 2.7a). Next, we performed 
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chromatin-immunoprecipitation (ChIP) PCR in human JURKAT T-ALL cells and found 
that MYC binds to the promoter region of UFD1 (Fig. 2.7b). 
 
c. Reanalysis of publicly-available ChIP-Seq data reveals MYC-binding peaks in the 
UFD1 promoter region 
 
Figure 2.8. MYC binds to the promoter region of UFD1 in human leukemic cells.  
 
Reanalysis of publicly-available ChIP-Seq data reveals MYC-binding peaks in the promoter region of UFD1.  
Top line denotes the gene locus of UFD1.  Black peaks represent ChIP-Seq signals of MYC in human 
JURKAT T-ALL cells.1  Orange line in the red-boxed area below the MYC binding region in JURKAT T-
ALL cells indicates the center of the above peak.  The three green-boxed areas denote MYC ChIP-Seq 
binding peaks in the acute myeloid leukemic K562 cells.3  Each box represents a peak cluster derived from 
multiple K562 experiments.  The darkness inside the box corresponds to signal strength.  The pink line in the 
green-boxed area indicates a high-scoring MYC-binding site where a conserved E-box (CACGTG) resides.  
 
Finally, analysis of published ChIP-Seq data, from experiments designed to identify 
MYC binding sites in human JURKAT and K562 leukemic cells,294, 295 further 
demonstrated that MYC binds to the promoter region of UFD1 (Fig. 2.8).  Analyses of 
human ENCODE databases revealed three MYC-binding elements, including a conserved 
E-box motif, in the promoter region of UFD1.  Together, our data indicate that MYC 
transcriptionally upregulates UFD1 in human leukemic cells.  
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3. MYC drives continuous upregulation of ufd1 during T-ALL development in vivo 
a. ufd1 is transcriptionally upregulated by MYC during tumor development in a zebrafish 
model of Myc-overexpressing T-ALL 
 
Figure 2.9. ufd1 is transcriptionally upregulated by MYC during tumor development in a zebrafish 
model of MYC-induced T-ALL.  
 
(a) EGFP-labeled T cells outline the normal thymus boundary of a control Tg(rag2:EGFP) fish 
(EGFP;ufd1+/+; 87-day-old; upper left panel).  EGFP-labeled T lymphoblasts in a Tg(rag2:EGFP-mMyc) 
fish (Myc) proliferate actively, invade into the local tissue (87-day-old; upper middle panel), and eventually 
disseminate throughout the host (151-day-old; upper right panel).  Arrows point to thymus (T).  Western blot 
analysis (lower panel) of EGFP-MYC and Ufd1 protein levels in EGFP+ T cells from fish described above.  
(b) Quantification of relative EGFP-MYC (left panel) and Ufd1 (right panel) to Actin ratios revealed that 
both MYC and Ufd1 protein levels increased gradually as the disease progressed (mean ± SD of EGFP-MYC 
to Actin ratio: 0.82 ± 0.15 for lymphoma cells vs. 2.12 ± 0.44 for leukemic cells, P=0.049; and Ufd1 to Actin 
ratio: 0.44 ± 0.29 for normal thymus, 2.54 ± 0.47 for lymphoma cells, and 6.52 ± 1.35 for leukemic cells, 
P=0.018 for thymus vs. lymphoma cells; P=0.049 for lymphoma vs. leukemic cells; P=0.012 for normal 
thymus vs. leukemic cells; n=3 per group).   
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To gain insight into the in vivo importance of UFD1 during MYC-mediated 
leukemogenesis, we studied a zebrafish model of T-ALL that overexpresses EGFP-fused 
mammalian Myc from a lymphocyte-specific promoter (rag2) and resembles a major 
subtype of human disease.24, 25 Western blot analysis was performed to detect Ufd1 and 
EGFP-MYC protein levels in the normal thymus from control Tg(rag2:EGFP) fish (EGFP) 
versus tumor cells from Tg(rag2:EGFP-mMyc) fish (Myc) at stages of disease onset and 
dissemination (Fig. 2.9a).  Compared to the control thymus, Ufd1 protein levels were 
significantly elevated in Myc-overexpressing T-ALL cells at disease onset and continued 
to increase as the tumors progressed, a pattern similar to that of EGFP-MYC protein levels 
(Fig. 2.9a-b). 
  
	79	
b. Zebrafish Myc-overexpressing T-ALL cells show evidence of increased ER stress 
 
Figure 2.10. Zebrafish Myc-overexpressing T-ALL cells show evidence of increased ER stress.  
 
(a) Western blot analysis of Bip and EGFP-MYC in normal thymocytes dissected from control 
EGFP;ufd1+/+ fish and T-ALL cells dissected outside of the thymus from Myc;ufd1+/+ fish (left panel).  
Actin serves as the loading control.  Protein quantification (right panel) revealed that Bip protein levels were 
significantly higher in T-ALL cells, compared to control thymocytes (Mean ± SD: 0.595 ± 0.108 vs. 0.0266 
± 0.012; P=0.006; n=3 per group).  (b) qRT-PCR analysis revealed elevated perk but not atf6 transcript levels 
in Myc-overexpressing T-ALL cells (Myc;ufd1+/+), compared with normal thymus (EGFP;ufd1+/+; Mean 
± SD of perk to b-actin ratio: 37 ± 13.8 vs. 1.07 ± 0.19; P=0.04; n=4 per group; left panel; and atf6 to b-actin 
ratio: 3.22 ± 1.27 vs. 1.74 ± 1.08; P=0.41; n=4 per group, right panel). Fish at 2-3 months of age were used 
for analysis.    
 
Bip protein levels were also elevated in these Myc-overexpressing T-ALL cells, 
compared to control thymocytes (Fig. 2.10a), indicating elevated ER stress.  Consistent 
with our observation in human patient samples, qRT-PCR analysis demonstrated a 
significant upregulation of perk but not atf6 transcript levels in these Myc-overexpressing 
T-ALL cells, compared to control thymocytes (Fig. 2.10b).   
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Figure 2.11. ufd1 is transcriptionally upregulated by MYC during tumor development in a 
conditionally regulated, 4-hydroxytamoxifen zebrafish model of MYC-induced T-ALL.  
 
qRT-PCR analysis revealed elevated ufd1 transcript levels in Myc-overexpressing T-ALL cells from each 
individual fish (Myc;ufd1+/+), compared with normal thymus dissected from each control fish 
(EGFP;ufd1+/+; Mean ± SD of ufd1 to β-actin ratio: 4.08 ± 0.77 vs. 1.03 ± 0.08; P=0.0055; n=3 and 4 fish, 
respectively; left panel); and downregulation of ufd1 in T-ALL cells from Tg(rag2:MYC-ER);Tg(rag2-
EGFP-bcl2) fish (MYC-ER;bcl-2) at 24 hours post 4-HT removal (Mean ± SD of ufd1 to β-actin ratio: 1.8 ± 
0.23 [+ 4-HT] vs. 1.02 ± 0.01 [- 4-HT]; P=0.0262; n=3 fish per  group; right panel).   
 
As in human T-ALL cells (Figs. 2.2, 2.3 and 2.5), the increase in Ufd1 protein 
levels was also driven by MYC-induced transcription in vivo, as shown by qRT-PCR 
analysis of ufd1 transcript levels in control thymocytes (EGFP;ufd1+/+) and Myc-
overexpressing T-ALL (Myc;ufd1+/+) cells (left panel of Fig. 2.11).  To address whether 
continued upregulation of ufd1 depends on MYC, we analyzed the Tg(rag2:MYC-
ER);Tg(rag2:EGFP-bcl2) zebrafish line, in which MYC activity is conditionally regulated 
by 4-hydroxytamoxifen (4-HT) and bcl2 overexpression precludes apoptosis upon MYC 
inactivation.296  Indeed, ufd1 transcript levels were significantly downregulated as early as 
24 hours after 4-HT removal (right panel of Fig. 2.11).  These data indicate that MYC 
activity accounts for the elevated ufd1 expression observed during T-ALL development. 
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4. Heterozygosity of ufd1 decreases the MYC-induced T-ALL burden and delays tumor 
progression without affecting animal health 
a. Heterozygous loss of ufd1 significantly decreases MYC-induced T-ALL burden and 
delays disease progression in zebrafish 
 
Figure 2.12. Heterozygous loss of ufd1 significantly decreases MYC-induced T-ALL burden.  
 
(a) Overlay of brightfield images and EGFP fluorescence of T cells in a control EGFP;ufd1+/+ and 
EGFP;ufd1+/- fish (123-day-old; left panels), as well as GFP+ tumor cells in a Myc;ufd1+/+ and 
Myc;ufd1+/- fish (114-day-old; right panels).  (b) Fluorescence intensity quantification demonstrated that 
Myc;ufd1+/- fish had significantly less tumor burden than Myc;ufd1+/+ fish (mean ± SD: 196,720 ± 72,740 
vs. 602,086 ± 112,985; P=0.017; n=5 per group; right panel), while there were no difference in thymic 
fluorescence intensity for EGFP;ufd1+/- versus EGFP;ufd1+/+ fish (mean ± SD: 4,539 ± 955 vs. 4,239 ± 
1,319; P=0.86; n=4 per group; left panel). Scale bar for panels (a) = 1 mM.   
 
To determine whether UFD1 is essential for MYC-driven T-ALL pathogenesis, we 
studied the zebrafish ufd1hi3471 mutant line,297 which harbors a retroviral insertion in the 
5’ UTR region of the ufd1 gene, leading to disruption of transcription and loss of gene 
expression.  After breeding the ufd1 heterozygous fish to the stable Myc transgenic fish, 
we observed a significant reduction of tumor burden in the Myc;ufd1+/- fish versus their 
Myc;ufd1+/+ siblings (right panels of Figs. 2.12a-b).  Notably, ufd1 heterozygosity did not 
affect non-transformed thymocytes in the control EGFP fish (compare fluorescence 
intensity of EGFP;ufd1+/+ vs. EGFP;ufd1+/- in left panels of Figs. 2.12a-b). 
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b. ufd1 heterozygosity leads to a 50% reduction of protein levels and does not impair           
T-ALL onset 
Figure 2.13. ufd1 heterozygosity leads to a 50% reduction of protein levels and does not impair T-ALL 
onset. 
 
(a) Western blot analysis of Ufd1 protein levels in control thymocytes and malignant lymphoblasts with or 
without ufd1 heterozygous loss.  (b) Protein quantification analysis revealed a 50% reduction of Ufd1 protein 
levels in both control thymocytes and malignant lymphoblasts upon ufd1 allelic loss, as well as a significant 
increase of Ufd1 protein expression in Myc-overexpressing lymphoblasts, compared to control thymocytes 
(mean ± SD of Ufd1 to Actin ratio: 1.34 ± 0.19 vs. 0.69 ± 0.12 for EGFP;ufd1+/+ vs. EGFP;ufd1+/-, and 
12.47 ± 0.44 vs. 6.25 ± 1.18 for Myc;ufd1+/+ vs. Myc;ufd1+/-; P=0.045 for EGFP;ufd1+/+ vs. 
EGFP;ufd1+/-; P<0.0001 for EGFP;ufd1+/+ vs. Myc;ufd1+/+; P=0.005 for EGFP;ufd1+/+ vs. 
Myc;ufd1+/-;  P=0.009 for EGFP;ufd1+/- vs. Myc;ufd1+/-; P=0.0025 for Myc;ufd1+/+ vs. Myc;ufd1+/-; 
n=4 for EGFP;ufd1+/+ and Myc;ufd1+/+ and 3 for EGFP;ufd1+/- and Myc;ufd1+/-, respectively).  Actin 
serves as the loading control.  P values were determined using student’s t-test.  (c) The rate of tumor onset is 
shown for Myc;Cre;ufd1+/+ (red line) and Myc;Cre;ufd1+/- (green line) fish. 
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Western blot analysis confirmed a 50% reduction of Ufd1 protein levels in both 
control EGFP;ufd1+/- thymocytes and Myc;ufd1+/- lymphoblasts, although Ufd1 protein 
levels in tumor cells were significantly higher than control thymocytes regardless of ufd1 
mutational status (Figs. 2.13a-b).  Next, we asked whether disruption of UFD1 function 
could inhibit T-ALL progression.  For this purpose we chose Tg(rag2:loxp-dsRED2-loxp-
EGFP-mMyc);Tg(hsp70-Cre) fish [designated as Myc;Cre],289 which develop T-ALL 
more slowly and with a wider window of time than the stable Myc [Tg(rag2:EGFP-mMyc)] 
line (45-250 vs. 35-60 days of life), permitting delineation of tumor onset and disease 
progression.289 290  
 
 
Figure 2.14. Heterozygous loss of ufd1 significantly delays disease progression in zebrafish.  
 
(a) Localized DsRED2-labeled tumors arose in a conditional Myc;Cre;ufd1+/+ (48-day) and 
Myc;Cre;ufd1+/-  fish (57-day); widespread dissemination of T-ALL was seen seven weeks later in 
Myc;Cre;ufd1+/+ fish, but not in Myc;Cre;ufd1+/- fish.  (b) Rates of T-ALL progression indicate that 
despite a similar tumor onset time, Myc;Cre;ufd1+/- fish (green line) develop widely disseminated T-ALL 
much slower than Myc;Cre;ufd1+/+ fish (red line; n=15 and 13; respectively).  Scale bar for panels (a) = 1 
mM.   
 
	84	
We then bred ufd1 heterozygous fish to the Myc;Cre double transgenic fish, 
subjected their progeny to heat-shock treatment to induce Myc expression, and monitored 
the fish for the time of tumor onset and progression as previously described. 289, 290 Despite 
no effect on tumor onset (Fig. 2.13c), heterozygous loss of ufd1 significantly suppressed 
the progression and distant dissemination of T-ALL in the Myc;Cre;ufd1+/- fish, compared 
to their Myc;Cre;ufd1+/+ siblings (Fig. 2.14).  By 399 days of life, 78% of the 
Myc;Cre;ufd1+/+ fish with tumor had wide T-ALL dissemination, in marked contrast to 
only 37% of the Myc;Cre;ufd1+/- fish with the disease (Fig. 2.14d).  
 
c. Heterozygosity of ufd1 does not negatively impact zebrafish embryonic development 
 
Figure 2.15. Heterozygosity of ufd1 does not negatively impact zebrafish embryonic development.  
 
(a) Brightfield images of embryos with the indicated genotypes at 4 (top) and 6 (bottom) days 
postfertilization (dpf; n=12 for ufd1+/+, 10 for ufd1+/-, and 4 for ufd1-/-, respectively).  The ufd1-/- fish 
develop a protruding jaw (blue arrow) starting at 4 dpf and fail to produce a swim bladder (red asterisk) by 
6 dpf.  (b) Overlay of brightfield and GFP-fluorescent images of EGFP;ufd1+/+, EGFP;ufd1+/-, and 
EGFP;ufd1-/- fish at 6 dpf (n=12, 17, and 5, respectively).  EGFP+ thymocytes (T) and red blood cells 
(RBC) were detected among all three groups of fish at this developmental stage.  Scale bar for panels (a-b) 
= 1 mM. 
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An important question was whether the reduced Ufd1 activity would impede 
normal development.  A visual screen of the progeny of ufd1 heterozygotes at 4, 6 and 9 
days postfertilization (dpf) failed to detect any morphologic or hematopoietic defects in 
these fish (ufd1+/-; Figs. 2.15a-b, middle panels), compared to wild-type siblings (ufd1+/+; 
Figs. 2.15a-b, left panels).  However, ufd1 homozygous mutants (ufd1-/-) exhibited 
developmental defects starting at 4 dpf (e.g., jaw protrusion) and failed to develop swim 
bladders at 6 dpf, despite apparently normal hematopoietic development (Supplementary 
Figs. 2.14a-b, right panels).  By 9 dpf, none of the ufd1-/- fish remained viable.   
  
	86	
d. Heterozygosity of ufd1 does not affect body weight or organ development in zebrafish 
 
Figure 2.16. Heterozygosity of ufd1 does not affect body weight or organ development in zebrafish.       
 
(a) The weight of male and female ufd1+/+ and ufd1+/- zebrafish was measured at 2.5, 6, and 15 months 
post fertilization (n≥4 fish per gender per age group).  There were no significant changes in weight as a result 
of either sex or ufd1 allelic status.  (b) Histological sections of 17-week-old ufd1+/+ and ufd1+/- fish were 
stained with hematoxylin and eosin, and revealed no gross morphological differences in all organs examined, 
such as thymus, gill, kidney, intestine, and testis (n=4 per group).   
 
 
Consistent with their lack of morphologic defects during embryonic stages, ufd1 
heterozygous fish were viable and grew at similar rates as their wild-type siblings into 
adulthood in the expected Mendelian ratios (Fig. 2.16a). Finally, histologic analysis of 
serial H & E-stained sections of 4-month-old ufd1+/+ and ufd1+/- siblings did not reveal 
any gross abnormalities in multiple tissues and organs from the heterozygous fish, 
including eye, brain, thymus, kidney, heart, liver, ovary, testis, intestine, and muscle (Fig. 
2.16b and data not shown).  These data demonstrate that ufd1 heterozygosity inhibits 
MYC-induced T-ALL pathogenesis without impairing normal fish development. 
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5. Heterozygosity of ufd1 induces apoptosis and inhibits cell proliferation in Myc-
overexpressing T-ALL cells in zebrafish 
a. Heterozygous loss of ufd1 induces apoptosis and inhibits cell proliferation in Myc-
overexpressing T-ALL cells but not in control thymocytes in zebrafish 
 
Figure 2.17. Heterozygous loss of ufd1 induces apoptosis and inhibits cell proliferation in Myc-
overexpressing T-ALL cells but not in control thymocytes in zebrafish.  
 
(a) FAC-sorted EGFP+ cells stained with anti-active caspase-3 (red; denoted by arrows)/DAPI (blue; n=3) 
from: EGFP;ufd1+/+, EGFP;ufd1+/-, Myc;ufd1+/+, and Myc;ufd1+/- fish.  (b) Quantification of active 
caspase-3+ cells revealed that a significantly higher percentage of tumor cells from Myc;ufd1+/- fish 
underwent apoptosis, compared to those in Myc;ufd1+/+ fish (mean ± SD of active caspase-3+ cells per area: 
8.69 ± 0.95 vs. 2.59 ± 0.53; P=0.005; n=3 per group).  There was no difference detected in number of active 
caspase-3+ thymocytes from EGFP;ufd1+/- vs. EGFP;ufd1+/+ fish (mean ± SD of active caspase-3+ cells 
per area: 0.42 ± 0.42 vs. 0.66 ± 0.44; P=0.71; n=3 per group).  (c) Cell cycle distribution of EGFP;ufd1+/+ 
vs. EGFP;ufd1+/- control thymocytes (left panel) and Myc;ufd1+/+ vs. Myc;ufd1+/- T-ALL cells (right 
panel).  Percentage of cells in G1/G0, S, or G2/M cell cycle phases is presented as mean ± SD; n=5-7 per 
group.  GFP-sorted control thymocytes dissected from thymus or tumor cells dissected outside the thymus of 
each fish (~2 months of age) were used for analyses.  Scale bar in (a) for upper panels = 10 µm and lower 
panels = 20 µm. 
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Figure 2.18. Heterozygous loss of ufd1 in zebrafish inhibits cell proliferation and induces apoptosis in 
Myc-overexpressing T-ALL cells but not in control thymocytes.  
 
(a) Annexin-V/PI (propidium iodide) staining revealed that allelic loss of ufd1 induced apoptosis only in 
Myc-overexpressing lymphoblasts. (b) Cell cycle distribution of EGFP;ufd1+/- control thymocytes vs. 
Myc;ufd1+/- T-ALL cells.  Percentage of cells in G1/G0, S, or G2/M cell cycle phases is presented as mean 
± SD; n=5-7 per group.  (c) Representative cell cycle plots of EGFP;ufd1+/+ vs. EGFP;ufd1+/- control 
thymocytes and Myc;ufd1+/+ vs. Myc;ufd1+/- T-ALL cells. n=5-7 per group.  GFP-sorted control 
thymocytes dissected from thymus or tumor cells dissected outside the thymus of each fish (~2 months of 
age) were used for analyses. 
 
To elucidate the cellular basis for this effect, we performed immunofluorescent 
staining for active caspase-3 to detect possible apoptotic cells in four groups of cells: 
EGFP;ufd1+/+ and EGFP;ufd1+/- thymocytes, as well as Myc;ufd1+/+ and Myc;ufd1+/- 
lymphoblasts (Fig. 2.17a).  Active caspase-3 staining revealed a significantly higher 
number of apoptotic cells among the Myc;ufd1+/- T-ALL cells, compared with control 
thymocytes or Myc;ufd1+/+ T-ALL cells (Figs. 2.17a-b). Similarly, Annexin-V/PI 
(propidium iodide) staining of these cells also revealed increased apoptotic cells in 
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Myc;ufd1+/- T-ALL cells (Fig. 2.18a).  To understand how ufd1 loss affects cell 
proliferation, we performed PI staining and flow cytometry analysis to examine DNA 
content in control EGFP;ufd1+/+ and EGFP;ufd1+/- thymocytes, as well as Myc;ufd1+/+ 
and Myc;ufd1+/- T-ALL cells.  Heterozygous loss of ufd1 did not cause any cell cycle 
changes in non-transformed thymocytes (EGFP;ufd1+/+ vs. EGFP;ufd1+/-; left panel of 
Fig. 2.17c, and Figs. 2.18b-c).  However, Myc;ufd1+/- tumor cells showed a significant 
increase in G0/G1-phase cells and a reduction of cells in S and G2 phase, compared to 
Myc;ufd1+/+ T-ALL cells or EGFP;ufd1+/- control thymocytes (right panel of Fig. 2.17c, 
and Figs. 2.18b-c).  Our data demonstrate that ufd1 heterozygosity induces apoptosis and 
decreases proliferation in Myc-overexpressing T-ALL cells but not in normal thymocytes.   
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6. UFD1 inactivation exacerbates ER stress, decreases cell growth, and induces apoptosis 
in human MYC-dependent T-ALL cells  
 
 
Figure 2.19. UFD1 inactivation in human T-ALL cells exacerbates ER stress, decreases cell growth, 
and induces apoptosis.  
 
(a) Growth curve of human JURKAT cells was analyzed after transducing with either a control Luciferase 
shRNA or two UFD1 shRNA hairpins.  The insert in panel (a) revealed that the two shUFD1 hairpins 
decreased about half of the UFD1 protein levels at day 4 postinfection.  The right panel illustrates relative 
growth rate of human JURKAT, MOLT3 and PEER T-ALL cells.  (b) Percentage of apoptotic cells upon 
UFD1 knockdown at day 9 or 10 postinfection in the above three cell lines.  Annexin-V staining was 
performed on cells isolated day 4, 6 and 9/10 postinfection, and apoptosis was detected as early as day 4 
postinfection.  (c) Genetic knockdown of UFD1 induces moderate cell cycle changes in human JURKAT 
cells.  At day 3 postinfection, cells were fixed and then stained with PI and analyzed by flow cytometry.  
Representative data from over three independent experimental repeats are shown. 
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Figure 2.20. UFD1 inactivation impairs ERAD and activates the proapoptotic UPR through the 
PERK-CHOP-BCL-2 axis in human T-ALL cells.  
 
(a) Western blot analysis of UFD1, CD3δ, BIP, IRE1α, ATF6, P-PERK, PERK, CHOP, BCL2, BCLxL, and 
cleaved PARP (clv-PARP) in JURKAT T-ALL cells at day 3 and 6 postinfection.  (b) Western blot analysis 
of UFD1, CHOP, BCL2, and clv-PARP in JURKAT T-ALL cells at day 6 postinfection (left panel).  Relative 
growth rate of human JURKAT T-ALL cells showed that CHOP knockdown rescued cell growth defects 
caused by UFD1 knockdown (right panel).  (c) Western blot analysis of UFD1, BCL2, and clv-PARP in 
JURKAT T-ALL cells that either overexpress GFP or BCL2 (left panel).  BCL2 overexpression rescued cell 
growth defects caused by UFD1 knockdown in JURKAT T-ALL cells.  Representative data from three 
independent experiments were shown (right panel).  ACTIN serves as a loading control. 
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Figure 2.21. Knockdown of UFD1 by shRNA decreases cell growth, exacerbates ER stress, and 
activates the proapoptotic UPR in human T-ALL cells.   
 
(a) Growth curves of human JURKAT and MOLT3 cells were analyzed after transducing with either a control 
Luciferase shRNA or two UFD1 shRNA hairpins that target the 3’ untranslated region (UTR) of the gene.  
The inserts in panel (a) revealed that the two 3’ UTR shRNA hairpins of UFD1 (shUFD1 #3 and shUFD1 
#4) reduced about 80% of UFD1 protein levels at day 3 postinfection.  (b) Growth rates of human JURKAT, 
MOLT3 and PEER T-ALL cells upon transduction of two 3’ UTR shRNA hairpins of UFD1, compared to 
cells transduced with a control Luciferase shRNA.  (c) Western blot analysis of the indicated proteins in 
human MOLT3 and PEER T-ALL cells at day 3 and 6 postinfection.  ACTIN serves as a loading control.  
Clv-PARP: cleaved PARP. 
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Our findings thus far suggest that targeting UFD1 could efficiently impair the 
ability of leukemic T cells to cope with ER stress, leading to their apoptotic death.  To test 
this hypothesis in human leukemic cells, we genetically inactivated UFD1 in JURKAT, 
MOLT3 and PEER cell lines, using two previously published shRNA hairpins (shUFD1 
#1 and #2; see Western blotting insert in Figs. 2.19a, 2.20a, and left panel of Fig. 2.21c),30 
as well as two hairpins that target the 3’ untranslated region of the gene and reduce ~80% 
of UFD1 protein levels (shUFD1 #3 and #4; see Western blotting inserts in Fig. 2.21a and 
right panel of Fig. 2.21c).   
 
 
Figure 2.22. UFD1 inactivation in human T-ALL cells exacerbates ER stress. 
 
 (a-b) Thioflavin T staining (red)/DAPI (blue) overlay (a) and quantification of thioflavin intensity (b) for 
JURKAT T-ALL cells treated with either vehicle or tunicamycin or transduced with the indicated shRNAs.  
Values represent the average of three independent experiments.  Scale bar in (a) = 5 µm 
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UFD1 knockdown by shRNAs significantly induced ER stress, as demonstrated by 
increased thioflavin staining (Fig. 2.22) and elevated BIP levels in human T-ALL cells 
(Fig. 2.20a and Fig.  2.21c).298-299  Moreover, these shRNAs significantly reduced the 
growth of all three T-ALL cell lines, with strong knockdown leading to a more severe 
inhibition of growth, compared to control cells transduced with shLuciferase (Fig. 2.19a 
and Figs. 2.21a-b).  To assess the dependency of T-ALL cells on UFD1 for survival, we 
stained JURKAT, MOLT3, and PEER cells with Annexin-V and PI, and found that UFD1 
inactivation robustly induced apoptosis in each cell line as compared to control cells 
transduced with shLuciferase (Fig. 2.19b).  Cell cycle analysis at day 4 postinfection 
revealed that UFD1 knockdown induced a modest but significant accumulation of G1-
phase cells and a reduction of S-phase cells in JURKAT T-ALL cells (Fig. 2.19c).  These 
data support the concept that human T-ALL cells depend on elevated UFD1 protein levels 
to cope with ER stress and indicate the potential of targeting this protein as a therapeutic 
option in high-risk cases. 
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7. UFD1 inactivation impairs ERAD and activates the proapoptotic UPR through the 
PERK-CHOP-BCL-2 axis in human T-ALL cells 
a. Knockdown of UFD1 by shRNA exacerbates ER stress and activates the proapoptotic 
UPR in human T-ALL cells 
 
UFD1 functions in the major ERAD complex downstream of the UPR to facilitate 
the retrotranslocation of misfolded/unfolded proteins from the ER lumen to the cytosol for 
proteolysis.287 We thus performed Western blotting to examine the protein levels of ERAD 
substrates and UPR components in human T-ALL cells.293, 300  UFD1 knockdown led to 
elevated levels of CD3δ (a known ERAD substrate of UFD1),301 ATF6, phospho/total 
PERK, but not phospho- or total IRE1α in JURKAT, MOLT3, and PEER T-ALL cell lines 
(Fig. 2.21a, Fig. 2.22c, and data not shown).  As expected, due to the difference in response 
kinetics of ER stress transducers,302 the expression levels of these proteins varied at 
different time points upon UFD1 inactivation in each cell line.  However, all three T-ALL 
cell lines upregulated phospho- and/or total PERK upon UFD1 inactivation.  Additionally, 
we observed upregulation of CHOP, a downstream effector of the PERK-mediated 
proapoptotic UPR.123 Because CHOP activation leads to downregulation of the 
antiapoptotic protein BCL2 and subsequent activation of ER-stress-induced apoptosis,146 
we performed Western blotting to analyze protein levels of BCL2, BCLxL, and cleaved 
PARP.  Indeed, UFD1 knockdown led to downregulation of BCL2 and BCLxL, as well as 
an increase in cleaved PARP in all three T-ALL cell lines tested, compared to control cells 
with shLuciferase knockdown (Fig. 2.20a and Fig. 2.21c).   
To determine whether the PERK-CHOP-BCL2 axis is crucial to the growth and 
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survival of human T-ALL cells, we transduced human JURKAT and MOLT3 cells with 
shCHOP and shUFD1, alone or in combination, and measured cell growth from day 4 to 
12 postinfection.  As expected, knockdown of UFD1 alone induced apoptosis and a 
significant decrease in cell growth, compared to control cells infected with shLuciferase 
(Fig. 2.20b and data not shown).  Although shCHOP alone slightly decreased cell growth, 
the combined knockdown of CHOP and UFD1 led to upregulation of BCL2 and rescue of 
the decreased cell growth (Fig. 2.20b and data not shown).  Overexpressing BCL2, a 
downregulated gene in the CHOP-mediated apoptotic axis, had the same effect in 
completely rescuing the decreased cell growth induced by UFD1 knockdown (Fig. 2.20c).  
These results demonstrate that UFD1 inactivation in MYC-dependent T-ALL cells disrupts 
ERAD and primarily induces the proapoptotic UPR through the PERK-CHOP-BCL2 axis. 
 
E. Discussion 
 
Tumor progression is facilitated by a number of adaptive mechanisms that enable 
malignant cells to survive and proliferate in a hostile microenvironment.303-304 Together 
with oncogenic stress, the adverse microenvironmental conditions, such as free radicals, 
low oxygen, nutrient deprivation, pH imbalance, and reactive oxygen species, all severely 
burden the ER with misfolded/unfolded proteins.  The ER quality control system, including 
the UPR and ERAD, is therefore critical for enabling cells to cope with ER stress.286  
Although others have demonstrated that MYC-dependent lymphoma and breast cancer 
cells activate the UPR to support tumor cell survival,227, 305 whether MYC regulates ERAD 
remains unclear.  Our findings show that while MYC-overexpressing T-ALL cells activate 
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the UPR, they simultaneously enhance ERAD through transcriptional upregulation of 
UFD1 to support leukemic cell survival.  UFD1 inactivation in MYC-dependent T-ALL 
cells led to an accumulation of its ERAD substrate CD3δ, indicative of defective ERAD 
function, and exacerbation of ER stress, as demonstrated by increased thioflavin T staining 
and BiP expression.  Importantly, ufd1 heterozygosity induced tumor-cell apoptosis and 
significantly impaired disease progression in the zebrafish model of MYC-induced T-
ALL.  Together, our results support the working model that MYC-enhanced expression of 
UFD1 promotes ERAD and mitigates ER stress, cooperating with the UPR to sustain tumor 
cell survival and disease progression.  Hence, our studies identify UFD1 as a novel 
contributor to MYC-mediated cancer aggressiveness.  
The role of the UPR in supporting tumor cell survival is of great interest for 
therapeutic exploitation in multiple human cancers.306   Interestingly, MYC-overexpressing 
T-ALL cells primarily activate the PERK-mediated UPR.  Although translation inhibition 
mediated by PERK activation can induce leukemic cell apoptosis,231, 307 we found that the 
decreased cell growth upon UFD1 inactivation was fully rescued through downregulation 
of CHOP or overexpression of BCL2, both of which are downstream effectors of the 
PERK-mediated proapoptotic UPR.  Thus, UFD1 inactivation in MYC-dependent T-ALL 
cells induces apoptosis primarily through the PERK/CHOP/BCL2 axis instead of through 
PERK-mediated translation inhibition or the ATF6-mediated UPR.  Earlier studies focused 
on targeting the PERK-mediated UPR as an anti-neoplastic approach.  However, PERK 
inhibitors were found to be highly toxic and cause diabetes.231  We show that a 50% 
reduction of UFD1 protein induces robust apoptosis and slows proliferation in T-ALL cells 
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but not in non-transformed thymocytes.  Underlying this difference is that non-malignant 
cells do not or minimally experience ER stress, while T-ALL cells are burdened with ER 
stress due to MYC overexpression and hostile microenvironmental conditions.  Our 
findings support the notion that UFD1 inhibition could serve as a productive approach to 
activate the PERK-mediated proapoptotic UPR and kill MYC-dependent tumor cells while 
minimally affecting normal cells.    
Among the three ERAD components, we found that MYC selectively upregulates 
UFD1 but not P97 or NPL4.  Although the involvement of P97 in cancers has been 
previously demonstrated,307 how P97 promotes tumorigenesis remains elusive.  Our studies 
suggest that the contribution of P97 to MYC-driven tumor development is largely mediated 
through UFD1. The enhanced UFD1 expression can compete P97 away from other adaptor 
proteins to enhance its ERAD function.  Although P97 inhibitors show preclinical anti-
neoplastic efficacy, they likely possess off-target toxicities given that P97 interacts with a 
myriad of adaptors beyond UFD1.308  Importantly, the enhanced UFD1 expression is 
observed in multiple human MYC-driven cancers besides T-ALL,280, 309 and predicts poor 
treatment outcome in ER+ breast cancer and lung cancer 
(http://kmplot.com/analysis/).  Therefore, besides treating MYC-overexpressing 
refractory/relapsed T-ALL, the therapeutic potential of directly targeting UFD1 could 
extend to patients with a broad spectrum of MYC-driven cancers, supporting the need to 
develop UFD1-specific inhibitors. 	  
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CHAPTER THREE: Evaluating the Therapeutic Implications of Targeting UFD1 
co-Factors to Treat Refractory/Relapsed T-ALL 
 
A. Abstract 
 
Endoplasmic Reticulum (ER)-associated protein degradation (ERAD) works to 
eliminate misfolded/unfolded proteins that have accumulated in the ER to be ultimately 
destroyed through proteasome- mediated degradation pathway. One class of ERAD 
modulators functions to inhibit this protein clearance pathway that is involved in the 
degradation of misfolded/unfolded proteins. This inhibition is predicted to trigger a strong 
stress response and decrease the survival of UPR dependent tumors. In particular, p97, an 
essential member of the AAA family of ATPases acts upstream of the proteasome as a key 
regulator of ERAD and the UPR. Here, we show that the p97 inhibitor CB-5083 has 
selective and robust activity against human MYC-overexpressing T-ALL cell lines, patient 
T-ALL samples, and in vivo zebrafish T-ALL models. Treatment of CB-5083 on human T-
ALL cells in vitro leads to the induction of the UPR and tumor-cell-apoptosis. In in vivo 
studies, using clinically relevant Myc-overexpressing zebrafish models of T-ALL, CB-
5083 both inhibits tumor growth and decreases tumor burden. These preclinical data 
demonstrate the stratified efficacy of CB-5083 in several T-ALL cell lines, providing a 
rationale for the clinical evaluation of CB-5083 in T-ALL patients. Furthermore, due to the 
known cytotoxicity of CB-5083 we examined the combinational effect of CB-5083 and 
ABT-199, a potent and selective BCL2 inhibitor, in an effort to decrease the necessary dose 
of CB-5083. In T-ALL cells with high BCL2 expression, the combination of CB-5083 and 
ABT-199 showed synergistic, anti-proliferation activity and robustly sensitized these cells 
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to CB-5083 treatment. Our results suggest that CB-5083 would be of greater clinical 
efficacy in T-ALL patients with particular genetic properties, and the combination of CB-
5083 with ABT-199 could afford enhanced anti-tumor activity to patients with these 
subtypes of T-ALL. 
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B. Introduction 
ERAD is one of the response mechanisms in the ER stress pathway that has recently 
emerged as a major drug target for therapeutic development in cancer. Specifically, ERAD 
participates in the retrotranslocation of misfolded/unfolded proteins from the ER to the 
cytosol in order to maintain protein homeostasis within the ER.310 In order to power this 
process, the cytosolic ATPase p97 functions as a ‘dislocase’ to extract misfolded/unfolded 
and polyubiquitinated proteins from the ER. Subsequently, p97 hands over these 
polyubiquitinated substrates to the proteasome for degradation. Defects in the ERAD 
process cause misfolded/unfolded proteins to accumulate in the ER, inducing ER stress and 
triggering the UPR.273  
The functional integrity of ERAD is not only essential for the maintenance of 
protein homeostasis, but for the survival of tumor cells as well. The uncontrolled 
proliferation of tumor cells requires the proteasome-mediated degradation of cell-cycle 
factors and the increased clearance of misfolded/unfolded proteins from the ER to avoid 
the induction of a proapoptotic ER stress response. Currently, there are small molecules 
(bortezomib and MG132) that directly target the proteasome, have demonstrated clinical 
validation, and serve as the SOC in both multiple myeloma and mantle cell lymphoma. 
However, the precise mechanism by which bortezomib and MG132 induce cytotoxicity in 
cancer cells remains elusive and long-term relapse of patients has expedited the 
development of second generation ERAD inhibitors.240 
One such second-generation strategy is to block ER substrate dislocation by 
targeting components of the ERAD machinery. Just prior to proteasomal degradation, 
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misfolded/unfolded proteins are transferred from the ER lumen to the cytosolic side of the 
ER wherein they are polyubiquitinated. This polyubiquitination acts as a signal for the 
cytosolic binding by the UFD1-NPL4-p97 complex. The translation of ATP hydrolysis into 
a mechanical force by p97 is essential for the delivery of ubiquitinated substrates to the 
proteasome. Recently, p97 inhibitors have been reported as a promising anti-cancer 
strategy. Eeyarestatin 1(Eer1) represents one of such inhibitors, and binds both the ER 
membrane and p97, preferentially inducing cancer cell death through the disruption of 
ERAD with effects similar to those induced by bortezomib.311, 312 N2,N4-
dibenzylquinalozoline-2,4-diamine (DBeQ) and its natural derivatives ML240 and ML242 
are reversible inhibitors of p97 ATPase activity. These inhibitors were found to be a potent 
activator of caspases in cancer cells, and inhibitors of both ERAD and autophagasome 
maturation.313  
Although these second-generation compounds have served as important tools in 
understanding the molecular consequences of inhibiting p97, they have modest potency, 
their specificity is not fully characterized, and they lack drug like properties for further 
clinical development. CB-5083 is a selective and potent inhibitor of the D2 ATPase domain 
of p97. The inhibition of p97 by CB-5083 profoundly activates all three ER stress 
transducers, with the primary mode of cell death caused by irresolvable proteotoxic stress. 
An early induction of caspase activity and cellular cytotoxicity is associated with an 
induction of CHOP and DRS expression; however, additional mechanisms of cellular 
cytotoxicity upon p97 inhibition have also been suggested. Encouragingly, CB-5083 has 
demonstrated strong antitumor activity in pre-clinical tumor models.273  
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Unfortunately, phase I clinical trials in multiple myeloma and non-small cell lung 
cancer have been recently terminated (NCT02223598 and NCT02243917). Given the 
potential role of p97 in normal cells and its multitude of adapters that implicate p97 in a 
diverse array of functional roles in the cell, it is of critical importance to establish the 
molecular determinants of tumor cell sensitivity to CB-5083. In doing this, patients that 
may have clinical sensitivity and respond to doses at well tolerated concentrations can be 
better identified. One strategy will be to screen a large panel of cancer cell lines to identify 
statistically significant genomic features that correlate with either CB-5083 sensitivity or 
resistance.   
T-ALL is an aggressive blood malignancy, that despite achieving cure rates of 80% 
in children and adolescents, less than 50% of adult patients fail to maintain remission 
status. Adult patients frequently show resistance to treatment and relapse with dismal 
prognosis due to multi-agent treatment complexities, gross cytotoxicity, and treatment 
expense.1 Thus, there is an urgent need to develop new agents that can intervene at specific 
therapeutic targets. Our analysis of the major ERAD complex components, UFD1-NPL4-
p97, in human T-ALL samples revealed that only UFD1 was significantly upregulated in 
high-MYC T-ALL patient samples compared to low-MYC patient samples and normal T 
cells. Moreover, our previous in vivo studies showed that the inhibition of UFD1 decreases 
tumor burden and delays tumor progression in Myc-driven zebrafish models of T-ALL. In 
vitro, reducing UFD1 levels with shRNA induces ER stress and the PERK mediated pro-
apoptotic UPR, demonstrating the potential of UFD1 as a therapeutic target. Unfortunately, 
UFD1 specific inhibitors are not available; therefore, we look to target p97 with current 
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available inhibitors that will act upon a component of the UFD1 ERAD complex. 
Our previous studies suggest that the contribution of p97 to MYC-driven T-ALL 
pathogenesis is largely mediated through UFD1. Thus, by utilizing the p97 ATPase 
inhibitor CB-5083 it could be possible to activate ER stress responses followed by the 
induction of apoptosis, similar to UFD1 inhibition. CB-5083 appears to be relatively 
selective for the ERAD-related functions of p97, making it an attractive treatment option 
for T-ALL, which exhibits pronounced ERAD and a presumed pronounced responsiveness 
towards pharmacologic agents that perturb the ERAD.  Moreover, the UPR acts as an 
enhancer of MYC-induced transformation, suggesting that inhibition of UPR components 
may be particularly effective against malignancies, like T-ALL, characterized by MYC-
overexpression. MYC is recognized as one of the most wanted targets for cancer therapy 
but is considered undruggable due to its nuclear localization, lack of a defined ligand 
binding site, and physiological functions essential for the maintenance of normal tissues-
lending to the absence of a clinically viable MYC inhibitor.226 Together, our studies 
described here suggest that there is a therapeutic rationale for targeting p97 in MYC-
expressing T-ALL. 
C. Materials and Methods 
1. Zebrafish Genotyping and Tumor Surveillance 
All transgenic and mutant fish were genotyped by gene-specific PCR using DNA 
isolated from either the whole embryo or the tail fin of the individual adult fish as 
previously described.289 Primer information is included in Table 3.1. Zebrafish were 
screened through the EGFP channel by fluorescent microscopy to monitor the progression 
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to disseminated T-ALL pre- and post-treatment with CB-5083 using a fluorescent 
microscope (MVX10; Olympus, Center Valley, PA, USA).   The images were subsequently 
quantified using Image J and processed using Adobe Photoshop (Adobe Systems 
Incorporated, San Jose, CA, USA). 
Primer Name	 Sequence	
rag2:EGFP-mMyc-F	 5’-ACAGCGTCTGCTCCACCTCC-3’	
rag2:EGFP-mMyc-R	 5’- TGGCCTCGGGATGGAGATGA-3’	
ufd1-wild-type -F	 5’-TTTGGAATAAACTTCCTCACATTTC-3’ 
ufd1-wild-type -R	 5’-TTTGGAATAAACTTCCTCACATTTC-3’ 
ufd1-mutant-F	 5’-CTGTTCCATCTGTTCCTGAC-3’	
ufd1-mutant-R	 55’-TTTGGAATAAACTTCCTCACATTTC- 3’   	
Table 3.1. Summary of primers used for zebrafish genotyping. 
 
 
2. Pharmacologic Treatment of Human T-ALL Cell Lines and Zebrafish 
T-ALL cell lines were cultured in the standard RPMI-1640 medium supplemented 
with 10% FBS, and PBMC in RPMI 1640 medium supplemented with L-glutamine and 
10% donor’s serum.  The low passage patient T-ALL cells from murine patient-derived 
xenografts were cultured in alpha-minimum essential medium (Thermo Fisher Scientific, 
Cambridge, MA, USA), containing 10% FBS and human AB serum (Sigma, St. Louis, 
MO, USA), 1% L-glutamine and penicillin/streptomycin (Thermo Fisher Scientific, 
Cambridge, MA, USA), 1x insulin-transferrin-selenium (Thermo Fisher Scientific, 
Cambridge, MA, USA), as well as 10 ng/ml recombinant mouse IL-7 and human IL-20 
(Peprotech, Rocky Hill, NJ, USA).  For viability assays, 1-2x104 cells per well were seeded 
in a 96-well plate with media containing CB-5083 (Active Biochem, Maplewood, NJ, 
USA) for 2 days, using cells treated with DMSO alone as controls.  Cell viability was 
measured by Cell Titer Glow or blue assay (Promega, Madison, WI, USA) and was 
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presented as a percentage of control cells. Calculations of combination index values and 
normalized isobolograms were generated using Calcusyn-Bisoft (BIOSOFT, Great 
Shelford, Cambride, UK). The Tg(rag2:EGFP-mMyc) transgenic fish (Myc) with T-ALL 
were subjected to CB-5083 treatment at 2.5-months of age.  Individual fish were soaked in 
100 ml of fish water containing the vehicle or 0.75 µM CB-5083 (Active Biochem, 
Maplewood, NJ, USA) in individual isolated chambers.  Fish water was refreshed every 3 
days for a period of one week.  Fish were imaged on day 0 and 7 of treatment through both 
brightfield and EGFP channels using a fluorescent microscope (MVX10, Olympus 
Corporation, Shinjuku, Tokyo, Japan).  Images were subsequently analyzed for tumor 
progression or regression by Image J based on the relative percentage changes in 
fluorescence intensity and tumor area on day 7 vs. day 0. 
 
 
3. Protein Extraction and Western Blotting  
Human T-ALL cells were lysed in RIPA buffer (1% NP-40, 0.1% SDS, 50 mM 
Tris-HCl pH 7.4, 150 mM NaCl, 0.5% sodium deoxycholate, and 1 mM EDTA) 
supplemented with Halt proteinase and phosphatase inhibitor cocktail (Thermo Scientific, 
Cambridge, MA, USA).  Primary antibodies included anti-MYC (Santa Cruz, Dallas, TX, 
USA or Cell Signaling, Danvers, MA, USA or Thermo Fisher, Waltham, MA, USA), anti-
UFD1 (Fitzgerald, Acton, MA, USA or Proteintech, Rosemont, IL, USA), anti-BCL-2, 
anti-spliced XBP1 and anti-ACTIN all from Santa Cruz (Dallas, TX, USA), as well as the 
following: anti-phospho-PERK, anti-CHOP, anti-BIP, anti-VCP/P97, anti-NPL4 and anti-
cleaved PARP, all of which were from Cell Signaling (Danvers, MA, USA).  Secondary 
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antibodies included horseradish peroxidase-conjugated anti-mouse or anti-rabbit 
antibodies (Pierce, Cambridge, MA, USA).  Autoradiographs were acquired with a G:BOX 
Chemi XT4 (Syngene, Frederick, MD, USA) and a CCD camera, and subjected to 
quantification analysis with ImageJ software.  
 
4. Statistical analysis   
Student’s t-test was used to analyze differences in protein expression, tumor 
burden, and cell viability between control and experimental group, or between any two 
groups of cells with different genotypes.  P-values equal to or less than 0.05 were 
considered statistically significant.  P-values were not adjusted for multiple comparisons. 
 
 
D. Results 
 
1. UFD1 interacts with p97 and NPL4 in human T-ALL cells 
 
 
Figure 3.1. Evaluation of significant residues for development of targeting therapeutics against 
UFD1.  
 
(a) Critical residues of UFD1 and the corresponding binding co-factors. The red (x) indicates where the 
disruption of interacting residues could potentially serve as efficacious drug targets. (b) Confirmation that 
UFD1 does interact with its known cytosolic co-factors, NPL4 and p97, in human T-ALL cells. 	
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In order to properly function as the major ERAD complex; UFD1, NPL4, and p97 
must interact with one another. Previous studies have identified the critical residues 
through which these co-factors interact. In Figure 3.1a, the red (x) indicates where the 
disruption of these critical binding interactions would lead to a loss of function of the 
ERAD complex. To confirm that the ERAD complex is in intact in T-ALL and efforts to 
target the complex would be fruitful, we performed a pull-down of the UFD1 protein in 
JURKAT, a human T-ALL cell line. Western blotting to confirm the pull-down of UFD1, 
also confirmed the presence of p97 and NPL4, indicating that in human T-ALL cells UFD1 
is interacting with its two ERAD complex co-factors.	
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2. CB-5083 differentially impacts viability of human T-ALL cell lines in vitro 
a. CB-5083 kills some T-ALL cell lines while others exhibit resistance 
 
 
 
Figure 3.2. Cytotoxic potency of CB-5083 in human T-ALL cell lines.  
 
(a), (b) and (c) Disruption of UFD1-mediated ERAD function via treatment with the p97 inhibitor CB-5083 
significantly reduced cell viability in a dose-dependent manner is demonstrated with increasing doses of CB-
5083 as measured by Cell-Titer Blue assays at 48-hour exposures. (b) and (c) T-ALL cell line viability is 
separated by cells with (b) exhibited sensitivity towards CB-5083 with an average Log IC50 of 2.104 or (c) 
exhibited resistance towards CB-5083 with an average Log IC50 of 2.495. 
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A block in ERAD following the inhibition of p97 is likely to lead to irresolvable 
proteotoxic stress. CB-5083 is an orally bioavailable inhibitor for p97 and was previously 
being tested in phase-I clinical trials for treatment of patients with multiple myeloma and 
advanced solid tumors (NCT02223598 and NCT02243917).  To characterize the potency of 
cell death following exposure to CB-5083, seven human T-ALL lines were treated with 
CB-5083. Following 48-hour exposure, CB-5083 showed IC50 values ranging from 11.49 
to 331 nm/L with a median IC50 value of 179.9 nm/L (Fig. 3.2a-c) and decreased viability.  
 
 
b. CB-5083 minimally affects viability of peripheral blood mononuclear cells 
 
 
Figure 3.3. Cytotoxic potency of CB-5083 in T-ALL and peripheral blood mononuclear cells.  
 
(a) CB-5083 more potently inhibits viability in human T-ALL cells, JURKAT and MOLT3 (red and orange 
lines), compared to peripheral blood mononuclear cells treated (PBMC; blue lines) demonstrated with 
increasing doses of CB-5083 as measured by Cell-Titer Blue assays at 48-hour exposures in human T-ALL 
cell lines and by Cell-Titer Blue assays at 48-hour exposures in PBMCs.  The insert in panel (a) revealed that 
CB-5083 treatment induced apoptosis in JURKAT cells at 48-hour exposures.  
 
Often, the levels of a drug target can influence the sensitivity to its inhibitor.  Most 
normal cells are not subject to stress and their UPR pathway is often in an inactive state, 
suggesting that selective inhibitors of the UPR may not affect normal cells. Tumor cells; 
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however, growing under stress often rely on an activated UPR for survival and thus an 
overexpression of ER stress response elements. This suggests a therapeutic window for 
agents targeting the UPR could be exploited. Therefore, we examined the pharmacologic 
effects of CB-5083 in JURKAT and MOLT3 human T-ALL cell lines and compared their 
sensitivity to peripheral blood mononuclear cells (PBMC). CB-5083 was significantly less 
potent in PBMCs compared with JURKAT and MOLT3 cells (Fig. 3.3). Moreover, we 
observed that CB-5083 treatment induced apoptosis in JURKAT cells as demonstrated by 
a time-dependent increased expression of cleaved-PARP at 8 and 30 hours after CB-5083 
treatment (Fig. 3.3). Taken together, our data show that human T-ALL cells are more 
sensitive to CB-5083 than PBMCs.  
 
3. CB-5083 kills human T-ALL cells through the robust induction of the UPR and 
apoptosis 
 
 
Figure 3.4. Robust induction of the UPR and apoptosis by CB-5083.  
 
CB-5083 activates UPR and apoptosis of human T-ALL cell line in vitro. (a) Human JURKAT T-ALL cells 
were treated with DMSO, 0.5, 3.75 or 5.0 µM Tunicamycin or 0.15, 0.5 or 2.0 µM CB-5083 for 8 hours. 
Protein lysates were subjected to Western blotting analysis of UPR-related proteins: anti-phospho-PERK, 
sXBP1, BiP and ACTIN antibodies. (b) The same protein lysates were subjected to Western blot analysis of 
apoptosis pathway proteins: cleaved-PARP, CHOP, BCL2 and ACTIN.  
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It is known that p97 knockdown or inhibition with small molecules has been shown 
to induce ER stress and activate all three arms of the UPR.273 Strong induction of the UPR 
as measured by phosphorylation of PERK, spliced XBP1, and BiP is observed upon 
treatment with CB-5083 (Fig. 3.4a). Moreover, CB-5083 treatment led to a robust 
expression of the transcription factor CHOP, with and similar expression levels to those 
observed upon ER stress induction with tunicamycin. The treatment of human T-ALL cells 
with CB-5083 consequently resulted in the activation of apoptosis as well. This activation 
of apoptosis is demonstrated by an increase in cleaved-PARP and a decrease in BCL2 
expression (Fig. 3.4b).  
 
4.	MYC-overexpressing T-ALL patient samples are highly sensitive to CB-5083 treatment 
 
 
Figure 3.5. Cytotoxic potency of CB-5083 in patient MYC-overexpressing T-ALL samples.  
 
(a) Patient T-ALL cells with elevated MYC expression (red and orange bars) were more sensitive to CB-5083 
treatment than those with lower MYC expression (purple and blue bars) at 48-hour exposure. The insert in 
panel (a) confirms the patient stratification of on the basis of MYC protein expression.  
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To determine whether CB-5083 can kill patient T-ALL samples, we next treated a 
number of patient T-ALL samples through collaboration with Dr. Michelle A. Kelliher, 
Professor at the University of Massachusetts.  Importantly, patient T-ALL samples with 
elevated MYC-expression (T-ALL-X-7, 14, and 3) were significantly more sensitive to CB-
5083 treatment than those with lower MYC-expression (T-ALL-X-15 and 2) (Fig. 3.5). 
Following 48-hour exposure, CB-5083 showed IC50 values ranging from 328.7 to 465.7 
nm/L with a median IC50 value of 352.6 nm/L. For those with elevated MYC expression, 
the mean IC50 value is 338.2 ± 7.21 nm/L and a mean IC50 value of 454.2 ± 11.55 nm/L for 
those patient samples with lower MYC expression (Fig. 3.5).  
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5. Evaluation of the synergistic potential of CB-5083 in combination with T-ALL 
standard of care and new-targeted therapy  
 
Figure 3.6. Evaluation of protein expression stratification by response to CB-5083 treatment. 
 
Western blotting analysis of the ERAD complex components UFD1, p97 and NPL4 and MYB, pTEN, 
MYC, BCLxL, and BCL2 in 13 human T-ALL cell lines stratified based on response to CB-5083 
treatment. ACTIN serves as the loading control.  
 
 
	115	
 
Figure 3.7. Combination with ABT-199 improves potency of CB-5083 in human T-ALL cells that 
exhibit resistance to CB-5083 treatment alone.  
 
 (a) CB-5083 (100 and 125 nM) synergizes strongly with ABT-199 (5 mM) in killing HSB2 T-ALL cells. 
Combination of CB-5083 with ABT-199 showed enhanced cytotoxic effect in HSB2 human T-ALL cells. 
(b) Combination indexes were determined after viability was normalized in the DMSO control groups and 
calculated by the Chou-Talay’s Combination Index Theorem.314 Cells were treated continuously with CB-
5083 and/or ABT-199 for 48 hours and then assessed for viability using Cell Titer Blue Assays.  
 
 
Figure 3.8. Combination with ABT-263 improves potency of CB-5083 in human T-ALL cells that 
exhibit resistance to CB-5083 treatment alone.  
 
 (a) CB-5083 (100 and 125 nM) synergizes strongly with ABT-263 (6.75 nM) in killing KARPAS45 T-ALL 
cells. Combination of CB-5083 with ABT-263 showed enhanced cytotoxic effect in KARPAS45 human T-
ALL cells. (b) Combination indexes were determined after viability was normalized in the DMSO control 
groups and calculated by the Chou-Talay’s Combination Index Theorem.314 Cells were treated continuously 
with CB-5083 and/or ABT-263 for 48 hours and then assessed for viability using Cell Titer Blue Assays.  
 
We next investigated whether the addition of CB-5083 to current T-ALL SOC 
induction therapy would lower the IC50 of CB-5083, as the inhibition of p97 not only 
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affects its ERAD functions but impacts its ability to be a functional adapter with its myriad 
of cellular co-factors. We treated JURKAT cells with a range of CB-5083 concentrations 
in the presence of doses from one of four compounds: vincristine, rapamycin, cytarabine 
and dexamethasone. The IC50 of CB-5083 was not lowered in any of these combinations, 
nor were any combination index (CI) values found to be between indicative of synergism 
as calculated by the Chou-Talay Theorem (data not shown).314 For anti-cancer agents, CI 
values between 0.9-0.4 are indicative of synergism. Specifically, CI values between 0.8-
0.9 are indicative of slight synergism; between 0.6-0.8 is indicative of moderate synergism 
and between 0.4-0.6 is indicative of strong synergism.  
Failing to find synergistic combinations between CB-5083 and SOC, we next 
investigated whether the blockade of both p97 and BCL2 could lead to enhanced 
cytotoxicity. BCL2 is an apoptotic regulator that has been shown to have a dominant role 
in the survival of multiple lymphoid malignancies.  Moreover, the association of the BCL2 
family members with tumor initiation and disease progression makes them attractive 
therapeutic targets.315 Previous treatment on a panel of human T-ALL cell lines indicated 
that some cell lines possess a greater sensitivity to CB-5083, such as JURKAT, MOLT3, 
MOLT16 and PEER (Fig. 3.2a-c). Thus, we investigated whether the sensitivity of these 
cell lines to CB-5083 and its expression of BCL2 could be further exploited by co-
treatment with ABT-199. Cells were treated with a range of CB-5083 concentrations in the 
presence of various dose levels of ABT-199. Only, the cell viability of JURKAT was 
slightly significantly decreased with the combination of CB-5083 and ABT-199 when 
compared to the single-agent treatment of CB-5083 (data not shown).  
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Western blotting analysis revealed that the cell lines most sensitive to CB-5083 
treatment had the lowest to no protein expression levels of BCL2, while cell lines resistant 
to CB-5083 treatment alone had detectable, high levels of BCL2 expression (Fig. 3.6). 
Thus, we investigated whether or not we could induce sensitivity to CB-5083 treatment by 
co-treatment with ABT-199. The resistant cell lines: KARPAS45, RPMO-8402 and HSB2 
were treated with a range of CB-5083 concentrations in the presence of various doses of 
ABT-199. A positive change and growth inhibition, and thus a significant increase in the 
killing effect of CB-5083 was observed in all three cell lines (Fig. 3.7a-b and data not 
shown).  
Unlike the differences in BCL2 expression between sensitive and resistant CB-
5083 cell lines, there was ubiquitous BCLxL expression amongst the panel. The compound 
ABT-263 preferentially binds to BCLxL. Therefore investigated co-treatment of a panel of 
cell lines with ABT-263, regardless of CB-5083 response, could further increase the 
sensitivity of these cell lines to CB-5083 and be robustly exploited amongst all T-ALL 
clinical presentations. Interestingly, only human T-ALL cell lines that were resistant to 
CB-5083 treatment alone exhibited a positive change and growth inhibition, and thus a 
significant increase in the killing effect of CB-5083 (Fig. 3.8 a-c). Notably, this response 
was not as robust for the CB-5083 resistant cell lines co-treated with ABT-199 and there 
were negative changes in growth inhibition for CB-5083 sensitive cell lines accompanied 
by a decrease in killing effects upon co-treatment (data not shown). In summary, our results 
yield a rational for co-treatment of CB-5083 resistant cell lines with ABT-199 or ABT-
263, with priority placed on ABT-199 co-treatment. Human T-ALL cell lines with 
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observed sensitivity to CB-5083 treatment alone do not positively respond to co-treatment. 
 
6. CB-5083 potency does not stratify by MYC expression amount different subtypes of 
human breast cancer cell lines 
 
Figure 3.9. Cytotoxic potency of CB-5083 in human breast cancer cell lines. 
 
 (a) Western blotting analysis of the ERAD complex components UFD1, p97 and NPL4 and MYC in five 
human triple negative breast cancer cell lines and nine human luminal breast cancer cell lines. Actin serves 
as the loading control. (b) Disruption of UFD1-mediated ERAD function via treatment with the P97 inhibitor 
CB-5083 does not significantly reduced cell viability when comparing two human triple negative breast 
cancer cell lines and two human luminal breast cancer cell lines in a dose-dependent manner as demonstrated 
with increasing doses of CB-5083 is measured by Cell-Titer Glo assays at 48-hour exposures. (c) Western 
blot analysis of UPR-related proteins in human breast cancer cell lines did not reveal protein expression 
stratification between two human triple negative breast cancer cell lines and two human luminal breast cancer 
cell lines. 
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 Our stratification of human T-ALL patient samples by UFD1 expression revealed 
a correlation with MYC expression as well. MYC-expression revealed a greater sensitivity 
to CB-5083 in our MYC-expressing T-ALL patient samples, enticing us to similarly stratify 
human breast cancer cells and treat them with CB-5083. Specifically, triple negative breast 
cancer (TNBC) is a subtype of breast cancer with high MYC-expression. Levels of MYC 
and UFD1 expression in luminal breast cancer cells (a subtype that frequently has low 
MYC-expression) were compared to TNBC cells (a subtype that frequently has high MYC-
expression) (Fig. 3.9a-b). We then treated two TNBC cell lines with high MYC expression 
(MDA-MB-231 and Hs578t) and two luminal cell lines with low MYC expression (MCF7 
and ZR-75-1) with CB-5083. The treatment of the cell lines does not remain equipotent in 
human breast cancer cell lines and sensitivity does stratify based on MYC expression levels 
(Fig. 3.9b). We further examined the expression signatures of ER stress response elements 
in these cell lines to determine if there was another means to stratify these samples; 
however, the expression of the UPR-related proteins also failed to stratify by subtype (Fig. 
3.9c). 
 
  
	120	
7. Pharmacological disruption of UFD1-mediated ERAD significantly delays disease 
progression in zebrafish 
 
Figure 3.10. Cytotoxic potency of CB-5083 in Myc-overexpressing zebrafish.  
 
(a-d) Adult stable Myc transgenic fish with T-ALL were treated for 7-days with vehicle or 0.75 µM of CB-
5083.  Images were captured on day 0 before treatment (a: vehicle, and c: CB-5083) and then seven days 
after continuous treatment (b: vehicle, and d: CB-5083). (e) A waterfall plot revealed that CB-5083 treatment 
significantly suppressed T-ALL progression and promoted disease regression in Myc fish (n=4 per group; 
P=0.03).   P values were determined using student’s t-test.  
 
 
a. CB-5083 treatment promotes MYC-induced T-ALL regression in zebrafish 
To determine whether pharmacological disruption of Ufd1-mediated ERAD could 
stall Myc-induced T-ALL progression in vivo, we treated our tumor-bearing, stable Myc 
transgenic fish with the p97 inhibitor CB-5083.  After 7 days of treatment with 0.75 µM 
CB-5083, all tumor-bearing Myc fish showed suppression of leukemic progression and 
distant dissemination (Fig. 3.10c-e), while tumors in the vehicle-treated group continued 
to grow and spread to distant regions (Fig. 3.10a-b and e; n=4 per group; P=0.03).  
Moreover, we observed apparent disease regression in 3 out of 4 fish treated with CB-5083 
(Fig. 3.10c-e).  Together, our data demonstrate that targeting UFD1-mediated ERAD using 
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P97 inhibitor can selectively kill MYC-overexpressing T-ALL cells and significantly 
decrease leukemia aggressiveness and progression. 
 
b. Cytotoxic effect of CB-5083 on zebrafish embryo development 
 To determine the effect of CB-5083 on zebrafish development, we treated embryos 
with vehicle or 0.125, 0.25, 0.5, 0.75, 1.0 or 2.0 µM of CB-5083 for six days. At three days 
and six days post-treatment, we observed the embryos for mortality and evidence of 
cytotoxicity. At six days post-treatment, embryos that received a 2.0 µM dose of CB-5083 
were deceased, while the embryos treated with the rest of doses remained viable. Moreover, 
red blood cells and EGFP+ thymocytes were detected and no gross abnormalities associated 
with the heart, jaw or swim bladders were observed. These results indicate that a 
concentration of CB-5083 that are effective in promoting tumor regression has minimal 
whole organism cytotoxicities.  
 
E. Discussion 
 Tumor cells grow continuously and require effective, high energy producing 
systems to sustain their high proliferation characteristics that set them apart from 
nontumorigenic cells. The regulation or inhibition of ERAD co-factors or components from 
an arm of the UPR have been suggested as potential cancer therapies. We have previously 
demonstrated that human T-ALL cell lines and patient samples upregulate a panel of ER 
stress response factors that act both in ERAD and the UPR compared to normal T cells. 
The inhibition of UFD1, a component of the major ERAD complex (UFD1-NPL4-p97), in 
vitro and in vivo resulted in decreased cell growth and proliferation, delayed progression 
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of T-ALL, decreased tumor burden, induction of apoptosis, and cell-cycle arrest. These 
observations suggest that the activity of inhibition towards the major ERAD complex in T-
ALL may represent an effective means against the intrinsic UPR response of tumorigenic 
cells. 
 The current study examines the functional consequences of the pharmacologic 
inhibition of p97 by CB-5083 in T-ALL models. CB-5083 is a potent and selective p97 
ATPase inhibitor. Specifically, CB-5083 exhibits selectivity to the p97 D2 ATPase 
domain, selectivity and competitively out binding ATP. CB-5083 inhibition leads to a 
direct block in ER extraction by blocking ERAD independent protein degradation as 
ubiquitin-tagged substrates can no longer be transported to the proteasome for 
degradation.273  
 On the basis of these considerations we set out to characterize the response to CB-
5083 in T-ALL models. We observed that nanomolar concentrations of CB-5083 were 
capable of inducing a significant decrease in viability for a majority of the T-ALL cell lines 
tested. The observed IC50 values for the T-ALL cell lines were significantly lower than 
those we observed in PBMCs when similarly treated with CB-5083. The exquisite 
sensitivity of T-ALL to CB-5083 could be explained by much higher levels of the ER stress 
response substrates at baseline, in comparison with PBMCs’. Significantly, we found a 
correlation between sensitivity to CB-5083 and MYC expression in T-ALL patient samples. 
This could be explained significant upregulation of UFD1 in the MYC-expressing T-ALL 
patient samples compared to those samples devoid of MYC expression. As a member of 
the ERAD complex, the upregulation of UFD1 may recruit p97 away from its other co-
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factors prioritizing its location within the cytosol of tumor cells, making the opportunity 
for p97 targeting by CB-5083 more abundant. 
 The preclinical activity of CB-5083 observed in multiple myeloma was associated 
with the potent induction of canonical markers of the UPR, including the phosphorylation 
of PERK, accumulation of sXBP1 and BiP, and the induction of CHOP.316 We similarly 
observe this induction of the UPR in JURKAT cells, in addition to the induction of the  
apoptosis factors cleaved-PARP and CASPASE-3, coinciding with a downregulation of 
BCL2. The observation that CB-5083 decreases the tumor burden in Myc-overexpressing 
zebrafish models is also notable. This model is considered to faithfully recapitulate a major 
subtype of MYC-driven leukemia of human T-ALL, suggesting that the treatment of MYC-
expressing T-ALL with CB-5083 could result in either the regression of disease or delay 
in pathogenesis, or both. Moreover, the treatment of zebrafish embryos with the maximum 
tolerated dose does not result in any gross morphologic abnormalities. 
An important area of investigation relates to the characterization of molecular 
markers that may identify T-ALL cases with pronounced responses to CB-5083 
monotherapy. Indeed, T-ALL patient samples with MYC expression and correlating 
upregulation of UFD1 exhibited more potent responses to CB-5083. Thus, we 
hypothesized that these criteria may help in stratification of other cancers that would have 
similar rapid responses to CB-5083. In comparing luminal (low MYC expression, low 
UFD1 expression) to triple negative (high MYC expression, high UFD1 expression) breast 
cancer, we were unable to recapitulate our findings. We may be better served to compare 
responses within sub-types or to further implore with human T-ALL cell lines and patient 
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samples if there are more complex mutational activation signatures that would exhibit a 
trend for a higher degree of responsiveness towards CB-5083. Development of such a 
signature in studies of larger cell line panels, complemented by samples from patients 
treated with CB-5083 may represent a means towards more accurate and precise 
stratification of T-ALL patients that would respond to CB-5083 treatment.  
As the characterization of CB-5083 as a monotherapy requires more effort, we 
looked towards the contribution of CB-5083 in different combinations. The therapeutic 
regime for T-ALL treatment is notoriously complex, requiring multi-agent regimes with 
great cytotoxicity, thus a relevant clinical aim is to reduce the concentration and number 
of doses a patient may have to receive. We first evaluated CB-5083 in combination with 
four of the drugs used in SOC induction therapy, the first stage in T-ALL treatment. In 
combination with these therapeutics, vincristine, rapamycin, cytarabine, and 
dexamethasone, CB-5083 at varying does did not elicit a synergistic response as 
represented by CI values that failed to fall between 0.4 and 0.9.  
However, we evaluated CB-5083 in combination with ABT-199, a compound that 
has potent and specific effect towards BCL2. It is known that T-ALL cell lines and primary 
patient sample are dependent upon BCLxL and in some cases there is a BCL2 dependence 
that correlates with the differentiation stage of the leukemic clone.317 In JURKAT T-ALL 
cells and T-ALL cells that exhibit resistance to CB-5083 treatment alone (KARPAS45, 
RPMO-8402 and HSB2), the combination of ABT-199 and CB-5083 resulted in the killing 
effect of CB-5083 and strong CI values around 0.6. In imploring the synergy of CB-5083 
and ABT-263, which preferentially binds to BCLxL-a dependency that is linked to a much 
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broader swath of T-ALL cell lines and primary patient samples we were only able to 
observe an increase in the killing effect of CB-5083 in human T-ALL cell lines that were 
previously characterized as resistant to CB-5083 treatment alone.317 These data 
promisingly suggest that CB-5083 resistance can be overcome with co-treatment of either 
ABT-199 or ABT-263 and further insinuate that CB-5083 is being maximally potent in 
human T-ALL cell lines that are already sensitive to CB-5083 treatment alone. 	  
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CHAPTER FOUR: Future Directions 
 
A. Introduction 
In the context of T-ALL, our research has demonstrated a collaborative response 
by ERAD and the UPR to ER stress induced by hostile tumor microenvironment and 
oncogene overexpression. The tumor microenvironment contributes to inducing ER stress 
through increased hypoxia, nutrient deprivation, alterations in pH, and the cytotoxicity of 
chemotherapeutic agents.318, 319 Moreover, MYC also contributes to increased levels of ER 
stress as its oncogenic deregulation leads to an increase in global translation and a surplus 
of mRNA being transferred into the ER.227 Fortunately, the ERAD complex, which has 
increased expression in T-ALL cell lines compared to thymus controls, works to mitigate 
this increased ER stress by retrotranslocating misfolded/unfolded substrates to the 
proteasome for degradation. Concurrently, the UPR activates signaling pathways that serve 
to adapt to ER stress and restore ER homeostasis in tumor cells. While these tumor cells 
may have increased levels of ER stress, the increased response of ERAD and UPR 
components maintains ER homeostasis within these cells and promotes tumor cell survival 
and progression (Fig. 4.1a) 
By disrupting the function of the ERAD complex through pharmacologic or genetic 
means, we observed an increase in the ER stress response elements in T-ALL cells. In 
addition to the tumor microenvironment and oncogenic stress impinging on the ER, there 
is now a failure from one branch of the ER stress response to resolve ER stress, further 
increasing the load of misfolded/unfolded proteins in the ER. Without a functioning ERAD 
complex, the UPR is unable to independently resolve ER stress and shifts from promoting 
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an adaptive response, to one where it must induce apoptosis. This induction of apoptosis is 
mediated through the PERK-CHOP-BCL2 axis of the UPR, ultimately leading to cell cycle 
arrest, apoptosis, and suppression of tumor progression (Fig. 4.1b). 
Remarkably, the long-term survival of standard risk ALL patients is approaching 
80% for pediatric patients that receive aggressive combination chemotherapy.65 However, 
this long-term survival is much more modest in adult patients whose staggering entrance 
into r/r T-ALL is followed by aggressive multi-agent treatments with gross cytotoxicity. In 
order to overcome these clinical challenges, the molecular events specific to T-ALL 
transformation that lend to disease aggressiveness and progression will need to be 
elucidated in vivo to corroborate our in vitro findings.  
The introduction and development of new therapeutics for T-ALL treatment also 
faces the challenge of testing in patients with aggressive disease and a unique panel of 
mutations. The prospect of developing an upfront, targeted therapeutic is even more 
cumbersome considering that novel therapeutics will probably work best in combination 
in addition to influences from molecular and biological patient stratification. The ER stress 
response is involved with a cytotoxic response mechanism in either a UPR dependent or 
independent manner; therefore, ER stress inducing agents are of great interest as potential 
anticancer therapies. Thus, treatment with commercially available ER stress response 
inhibitors or the development of UFD1 specific inhibitors will need our further pre-clinical 
assessment. 
Activation of at least one branch of the UPR has been reported in a number of 
cancers and many ER chaperones and UPR target genes show increased expression in 
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human tumor samples.226 The role of UPR in different forms of cancer isn’t fully 
characterized at present, and it remains unclear how tumor cells adopt to long-term ER 
stress in vivo. Whether the protective elements of the ER stress response are enhanced, the 
destructive components suppressed or if the compromised apoptotic machinery is 
insufficient to sensitize tumor cells to UPR targeted pharmacologic agents also needs to be 
resolved.  
 
B. Discussion 
1. Study of the molecular mechanisms by which UFD1 inhibits tumor aggressiveness in 
vivo 
a. Establishing the cytosolic role of UFD1 in T-ALL pathogenesis 
 
Figure 4.1. Schematic diagram to summarize our findings and working model. 
 
 (a) A tumor cell with UFD1 activation. (b) A tumor cell with UFD1 inactivation. 
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The ERAD complex, UFD1-NPL4-p97 functions in the ubiquitin proteasome 
pathway, which is one component of the ER stress response. In this pathway, target proteins 
are first recognized by upstream components and tagged with polyubiquitin chains. These 
polyubiquitinated substrates are then taken to the 26S proteasome to be degraded. The 
UFD1-NPL4-p97 complex serves in the middle of this proteasome-based pathway. The 
complex functions in the recognition of several polyubiquitinated proteins and facilitates 
their presentation to the proteasome for specific processing or processive degradation. 
These actions carried out by the UFD1-NPL4-p97 complex are sequestered to the 
cytosol.265, 270, 279 
This working model that we have characterized for UFD1’s cytosolic function is 
largely the result of in vitro experiments. Fortunately, we have well established models of 
Myc-driven leukemia in zebrafish that aided in the identification of the functional impact 
of UFD1. The translation of our in vitro findings to an in vivo context will provide even 
more physiological relevant results regarding the molecular functions of UFD1 in 
leukemogenesis. The zebrafish model will aid in studying the mechanisms of proteolysis 
and tumor progression. Specifically, the zebrafish model of MYC-induced T-ALL 
recapitulates the major subtype of human disease overexpressing the TAL1 and LMO1/2 
oncogenes.320, 321 Thus imaging and genetic capabilities, in addition to the high 
conservation of the ER stress response and proteolytic pathways, will complement our 
previous in vitro studies in human cancer cells providing a comprehensive mechanistic 
study that could be utilized for development of targeted therapeutic strategies. 
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b. Elucidating the nuclear function of UFD1 in T-ALL pathogenesis 
 Despite UFD1’s cytosolic function, it is known that UFD1 has functions other than 
ERAD that aren’t centralized to the ubiquitin proteasome pathway. In the nucleus, under 
normal conditions, UFD1 acts as a scaffold for SKP2 and the deubiquitinating enzyme 
USP13, antagonizing the ubiquitination of SKP2. However, under prolonged ER stress 
nuclear UFD1 levels are downregulated, triggering SKP2 destabilization and an 
accumulation of p27-leading to a delayed cell cycle progression in G1.263 This 
demonstrates that UFD1 facilitates the degradation of misfolded/unfolded proteins in G1-
arrested cells, insinuating that there is a link between UFD1 and cell cycle controls that 
would additionally serve to optimize ERAD. 
 This nuclear response of UFD1 in regulating ER stress has not been elucidated in 
the context of tumor microenvironments that provoke increased levels of ER stress. 
Understanding how nuclear UFD1 responds to this harsh tumor microenvironment and 
serves an additional role in ERAD will be of critical importance. Upon better understanding 
of the nuclear molecular response of UFD1 in T-ALL, we can then begin to understand 
how this response would coordinate with the cytosolic response of UFD1 in reducing ER 
stress. The elucidation of the nuclear and cytosolic responses of UFD1 under ER stress will 
provide resolution to the temporal and spatial activation signature of UFD1, leading to a 
foundational understanding on the orchestration of tumor progression and identification of 
more potent therapeutic windows when targeting UFD1. 
Our preliminary data demonstrate a connection between Ufd1 and Skp2 in T-ALL. 
Skp2 protein levels were analyzed from zebrafish Myc-overexpressing T-ALL cells with 
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or without ufd1 allelic loss. Cells with ufd1 allelic loss had more than a two-fold 
downregulation of Skp2 protein levels. This relationship, along with the relationship with 
Usp13, will need to be further investigated both in vivo and in vitro.   
 
2. Generating and evaluating UFD1 specific inhibitors 
While there is much to learned from extensive patient stratification and potentially 
fruitful results in the treatment of T-ALL with CB-5083, CB-5083 remains an extremely 
cytotoxic agent with a myriad of off-target effects. This is largely due to the fact that p97 
has many adaptors that direct its function to critical physiological pathways in the cell. 
Rather, we propose focusing on the development of UFD1 specific inhibitors. The 
characterization of critical interacting residues in UFD1 and the resolution of crystal 
structures are extensive and nearly complete.253-257 Moreover, we know that the UFD1-
NPL4-p97 complex is intact and functioning in human T-ALL cells (Chp.3; Fig. 3.1b).  
It is known that UFD1 has functions beyond its role in ERAD that could 
dramatically impact the cell if a total loss of UFD1 was incurred. Rather, we suggest 
focusing on the development of an inhibitor that would target the polyubiquitin pocket of 
UFD1. The polyubiquitin pocket is solely responsible for the identification of polyubiquitin 
moieties at the ER lumen and aiding in their subsequent transfer to the proteasome.249 The 
targeting of this specific moiety would lead to an accumulation of ERAD substrates leading 
to the induction of the UPR (Chp.3; Fig. 3.1a). An unresolved accumulation of substrates 
within the ER caused by a dysfunctional ERAD complex, would likely lead to the 
activation of the proapoptotic response of the UPR. While the number of unfolded moieties 
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reaches a critical threshold in the ER upon polyubiquitin-specific inhibition, UFD1 would 
still be able to use its monoubiquitin-specific binding pocket in lipid synthesis and carry 
out its nuclear role as a scaffold protein. Moreover, its roles in nuclear envelope formation 
and chromatin decondensation would likely remain unimpacted-although the normal 
UFD1 function in these activities needs to be further characterized. 
Our characterization of UFD1 in the pathogenesis of T-ALL has revealed its 
essential role in the maintenance of tumor progression and integrity of ERAD under the 
pressures of the tumor microenvironment. The inhibition of UFD1 in MYC-driven 
leukemogenesis reduces tumor burden and inhibits tumor progression. Molecularly, this 
inhibition of UFD1 results in the activation of the PERK-mediated, pro-apoptotic ER stress 
response and cell-cycle arrest. Pharmacologic treatment of UFD1 with the ERAD complex 
inhibitor CB-5083 shows a preferential response in T-ALL cells compared to PBMCs. 
Moreover, in T-ALL patient samples a greater sensitivity to CB-5083 is observed in MYC-
expressing samples. These in vivo and in vitro results, in addition to promising 
pharmacologic implications, underscore the urgency to continue the characterization of the 
nuclear role of UFD1 and develop a treatment protocol that identifies ideal recipients for a 
UFD1 specific inhibitor.  
 
 
3. Identification of biomarkers to predict treatment response 
Previous efforts have been made to identify biomarkers from the ER stress response 
pathway that are correlated with poor clinical outcomes and aggressive tumor behavior. 
Thus far levels of spliced XBP1 and BiP have been used to make these associations in 
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gastric carcinomas, gliomas, prostate, and breast cancer.219, 229, 326, 327  However, there has 
been no such identification of any blood-based biomarker or mutational signature found in 
T-ALL with regards to the ER stress factors. Indeed, we observed an upregulation of ER 
stress response factors in T-ALL patient samples as compared to normal T-cells. 
Furthermore, we noticed that in MYC-overexpressing T-ALL patient samples there was a 
significant overexpression of UFD1 compared to non MYC-overexpressing samples. When 
treated with the ERAD CB-5083, which potently targets p97, those patient samples with 
MYC-overexpression were more sensitive to drug treatment compared to non MYC-
overexpressing patient samples. Perhaps the activation of the ER stress factors and MYC-
overexpression could serve as the foundation for the stratification of patients that would 
respond to a pharmacologic disruptor of an ER stress response pathway. 
 Notably, we have not validated a similar RNA or protein expression pattern in 
human T-ALL cell lines. However, we similarly observe a dichotomous response to the 
pharmacologic agent CB-5083 in a panel of human T-ALL cell lines. Corroborating our 
patient T-ALL samples with our human T-ALL cell line data, we should be able to start 
developing a more precise mutational/expression profile that would help in accurate 
stratification of T-ALL patients. To undertake this stratification, we would look at both T-
ALL patient samples and human T-ALL cell lines that responded to CB-5083 and compare 
those to less-sensitive responders of CB-5083 treatment. Within each subgroup, the 
available RNA sequence data and protein expression can be examined to determine if there 
is a correlating genetic signature to CB-5083 response. These findings would help in 
preclinical testing and in the organization of future clinical trials of CB-5083 by directing 
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CB-5083 treatment to those that are most likely to respond, rather than unnecessarily 
subjecting patients to the very cytotoxic agents, based on genetic profiling. Moreover, these 
parameters could be useful in determining primary and secondary endpoints for CB-5083 
clinical trials, which unfortunately have experienced early terminations. 
 
4. Elucidation of mechanisms of resistance to UFD1 pathway inhibition 
Upon genetic inactivation of UFD1, we observed an increase in the PERK-CHOP-
BCL2 proapoptotic axis of the UPR. Moreover, upon pharmacologic inhibition of the 
UFD1 ERAD co-factor p97, we also observed an upregulation of this cytotoxic response. 
Noticeably, upon CB-5083 treatment of human T-ALL cell lines there was a dichotomous 
response wherein some cell lines were more sensitive to the CB-5083 treatment than others. 
This dichotomous response also held true when we treated patient T-ALL samples with 
CB-5083. In both instances, the samples that were not responsive to CB-5083 treatment 
had increased ATF6 and IRE1α expression. ATF6 and IRE1α also function as stress 
transducers in the UPR. Upon their activation, ATF6 and IRE1α initiation well-defined 
adaptive stress response cascades. The prolongation of ATF6 and IRE1α signaling during 
ER stress can promote cell survival, serving as an important adaptive mechanism to match 
the ER folding capacity with demand. Thus, the upregulation and activation of these 
pathways in certain samples may serve as a resistance mechanism towards CB-5083 or 
UFD1-pathway inhibition. Although CB-5083 treatment and UFD1-pathway treatment 
increase ER stress, it is not to a degree that overwhelms the ATF6 and IRE1α stress 
response capacity.  
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 Thus, ATF6 and IRE1α and their correlating downstream signaling pathways must 
be further investigated to determine if the activation of these transducers is indeed enough 
to confer resistance to CB-5083 treatment. The protein expression levels of factors 
downstream of ATF6 and IRE1α must be implored to confirm activation of the transducers 
at the ER lumen, but these levels must also be implored to determine if there are other 
unique features that may also confer resistance to CB-5083 treatment. Additionally, further 
investigation into the RNA expression signatures of cells should be examined to 
corroborate findings from protein expression analysis and further aide in the identification 
of T-ALL samples that will also likely be resistant to CB-5083. 
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